Compositions and methods for decreasing ferroptotic alveolar cell death

The application of AKR1B8 from Foxj1⁺ ciliated cells and extracellular vesicles addresses the lack of interventions for ALI/ARDS by reducing ferroptotic alveolar cell death and lung injury, enhancing pulmonary function and survival.

WO2026241259A1PCT designated stage Publication Date: 2026-11-19YALE UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027797
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current pharmacological interventions are lacking for Acute Lung Injury (ALI) and its severe form, Acute Respiratory Distress Syndrome (ARDS), which are characterized by diffuse alveolar damage and high mortality rates, primarily due to incomplete understanding of pathogenesis and pulmonary cell responses to inflammation.

Method used

The use of aldo-keto reductase AKR1B8, produced by Foxj1⁺ ciliated cells, to protect alveolar cells from ferroptotic death through the knockout of the Wnt receptor FZD6, and the administration of extracellular vesicles containing AKR1B8 to mitigate lung injury, along with the use of ferroptosis inhibitors.

Benefits of technology

Reduces lipid peroxidation, alveolar cell death, and lung injury by suppressing ferroptosis, thereby improving pulmonary function and reducing mortality in ALI/ARDS.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027797_19112026_PF_FP_ABST
    Figure US2026027797_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are compositions and methods for treating a subject having lung inflammation. The methods include administering a composition including a liposome and an aldo-keto reductase family 1 (AKR1) protein associated with the liposome to a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No. 047162-7558 WO 1 (02937)

[0002] COMPOSITIONS AND METHODS FOR DECREASING FERROPTOTIC ALVEOLAR

[0003] CELL DEATH

[0004] CROSS-REFERENCE TO RELATED APPLICATION

[0005] The present application is entitled to priority under 35 U. S. C. § 119(e) to U. S.

[0006] Provisional Patent Application No. 63 / 804,422 filed May 12, 2025, which is herein incorporated by reference in its entirety.

[0007] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0008] This invention was made with government support under HL 135805 awarded by National Institutes of Health.

[0009] SEQUENCE LISTING

[0010] The XML file named “047162-7558WO1” created on May 7, 2026, comprising 5,708 bytes, is hereby incorporated by reference in its entirety.

[0011] BACKGROUND OF THE DISCLOSURE

[0012] Acute Lung Injury (ALI) and its severe form, Acute Respiratory Distress Syndrome (ARDS), represents a serious health problem with high mortality rates 1,2. ALI / ARDS is commonly caused by bacterial and viral lung infections and is characterized by diffuse alveolar damage, neutrophilic inflammation, and increased permeability of the alveolar-capillary barrier, leading to protein-rich edema and subsequent impairment of arterial oxygenation.

[0013] The incidence of ALI / ARDS is reported to be around 200,000 per year in the US with a mortality rate of around 40% before the current COVID- 19 pandemic. COVID- 19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the death rate of about 1.2% of cases probably due to massive alveolar damage and progressive respiratory failure before the vaccination. Strong association of COVID- 19 and previous SARS-CoV or Middle Eastern respiratory syndrome (MERS) has been established with ARDS.

[0014] Currently there are no pharmacological interventions for ALI / ARDS. The incomplete understanding of ALI / ARDS pathogenesis and pulmonary cell responses to inflammation hampers the progress in ALI / ARDS therapeutic development.

[0015] Accordingly, there is a need in the art for articles and methods that improve on

[0016] 1

[0017] 578332772

[0018] Attorney Docket No. 047162-7558 WO 1 (02937)

[0019] existing compositions and methods for treating acute lung inflammation.

[0020] BRIEF DESCRIPTION OF THE DRAWINGS

[0021] FIGs. 1 A-1D show global Fzd6 KO ameliorates LPS-induced lung injury. FIG. 1A. Global inducible Fzd6 KO (Fz<76KIx) mice and their wildtype (Wt) controls were subjected to lung inflammation induction by intratracheal administration of LPS. The protein and FITC-BSA contents in the BALs were determined 18 hours later. FIG. IB shows lung injury scores obtained from histomorphometry analysis of lung sections of mice described in FIG. 1A. FIG. 1C shows the amount of cytokines in the BALs of mice in FIG. 1 A as determined by ELISA. FIG. ID shows the abundance of BAL and lung myeloid cells of mice in FIG. 1 A determined by flow cytometry. Data in FIGs. 1A-1D are presented as means±sem (two-tailed Student’s t-test, n>5). Each datum point represents one mouse.

[0022] FIGs. 2A-2E show a lack of Fzd6 in Foxjl+cells ameliorates LPS-induced lung injury. FIGs. 2A-2B show uniform manifold approximation and projection (UMAP) clustering of lung CD45-negative (FIG. 2A) and positive (FIG. 2B) cells based on single-cell RNA sequencing of a Wt lung. Expression of cell-type marker and Fzd6 genes are shown. FIG. 2C shows the expression of Fzd6 in the clusters shown in A. FIGs. 2D-2E show the results of Fzd6Foxj1CKO (Fzd6Fj1) and Wt mice subjected to LPS-induced lung inflammation and 30 min later administered mock or ferrostain-1 (Feri) via I. V. injection. Lung permeability and histomorphometry analyses were conducted 18 hours later. Data in FIGS.

[0023] 2D-2E are presented as means±sem (two-way ANOVA, n>5). Each datum point represents one mouse.

[0024] FIGs. 3A-3G show that the Fzd6Foxj1CKO alters gene expression in lung cells from LPS-treated mice. FIG. 3A shows UMAP clustering of CD45-negative lung cells sorted from two pairs of Wt and Fzd6Foxj1CKO mice. FIG. 3B shows cell type marker gene expression (Exp) of the clusters shown in FIG. 3A. FIG. 3C shows cell numbers of each cluster in FIG.

[0025] 3A for the wildtype (Wt) and Fzd6Foxj1CKO (KO) samples. FIGs. 3D-3G show Ingenuity Pathway Analysis (IP A) of differentially expressed genes between wildtype and Fzd6Foxj1CKO in these clusters. Pink columns represent upregulated pathways in Fzd6Foxj1CKO, whereas blue columns represent downregulated ones. Open columns represent undetermined regulation direction.

[0026] FIGs. 4A-4J show that the Fzd6Foxj1CKO suppresses ferroptotic alveolar cell death in LPS-injured lungs. FIGs. 4A-4B show the results of the Fzd6Foxj1CKO (Fzd6Fj1) and Wt mice

[0027] 2

[0028] 578332772

[0029] Attorney Docket No. 047162-7558 WO 1 (02937)

[0030] being treated as described in FIG. 1. The lung sections were stained with anti-4-HNE, and 5 independent sections from each mouse were quantified (FIG. 4A). The BAL MDA contents were also determined from these mice (FIG. 4B). FIG. 4C shows lung sections from a Wt mouse that was treated as in FIG. 1 A and stained with antibodies as indicated. FIG. 4D shows the results of Fzd6Foxj1CKO (Fzd6Fj1) and Wt mice being treated intratracheally with LPS for 9 hours and perfused with PI immediately before sample collection. Some of the Wt mice were given intravenously with ferrostain-1 (Feri) immediately after LPS treatment. The ratios of PI to DAPI signals were quantified from 5 independent sections per mouse lung. FIGS. 4E-4J show lung sections from the Fzd6Foxj1CKO (Fzd6Fj1) and Wt mice that w ere treated as in FIG. 4D and stained with antibodies as indicated. Data in FIGs. 4A, 4B, and 4D are presented as means±sem (FIG. 4A, two-way ANOVA, n>3; FIG. 4B. two-tailed t-test, n>5; FIG. 4D, one-way ANOVA, n=5). Each datum point represents one mouse.

[0031] FIGs. 5A-5H show that ferroptosis inhibitors and Fzd6Foxj1CKO ameliorate lung injury in MHV-infected lungs. FIGs. 5A-5D show the results of Wt mice infected intranasally with MHV-A59 and treated with mock (Ctr), ferrostain-1 (Feri) or liproxstatin-1 (Lipl). Two days later, the mice were given FITC-BSA intravenously one hour and PI infusion immediately before tissue collection. Representative images are shown (FIG. 5A). The quantification of the ratios of Pl-positive to DAPI stained cells is shown in FIG. 5B. Lung injury phenotypes are shown in FIGs. 5C-5D. FIGs. 5E-5H. The Fzd6Foxj1CKO (Fzd6Fj1) and Wt mice were infected with MHV-A59 and given with PI and FITC-BSA as in FIG. 5 A. The quantification of the ratios of Pl-positive to DAPI stained cells is shown in FIG. 5E. BAL MDA is shown in FIG. 5F. Lung injury phenoty pes are shown in FIGs. 5G-5H. Data in FIGs.

[0032] 5B-5H are presented as means±sem (one-way ANOVA for FIGs. 5B-5D; two-tailed Student's t-test for FIGs. 5E-5H; n=5). Each datum point represents one mouse.

[0033] FIGs. 6A-6K show that the Fzd6 KO increases expression oiAkrlb8 that suppresses cell death in LPS-injured lungs. FIG. 6A shows Akrlb8 expression in the 5 clusters classified in FIG. 3 A of Wt and Fzd6Foxj1CKO (Fzd6Fj1samples. FIG. 6B is a volcano plot of differentially expressed genes in Foxj cluster 1 cells shown in FIG. 3 A. FIG. 6C shows lung sections from the Wt, Fzd6Foxj1CKO (Fzd6Fj1), and AKR1B8 KO (AkF / _) mice that were treated with PBS or LPS as in FIG. 1 were stained with antibodies as indicated. FIG. 6D shows Western blotting detection of ARK1B8 in the BAL concentrates from Fzd6Foxj1CKO (Fzd6Fj1) and Wt mice subjected with LPS-induced lung injury. Quantification of AKR1B8 normalized against the total BAL protein are shown. FIG. 6E shows the effects of conditioned medium (CM), EV preparation (EV), and EV-depleted CM (dEV) on RSL3- 3

[0034] 578332772

[0035] Attorney Docket No. 047162-7558 WO 1 (02937)

[0036] induced HEK293 cell death. EV and dEV were adjusted to the same final volumes equivalent to the original CM concentrates. The numbers denote the volumes (pL) added to the assay. The live cell number without RSL-3 was taken as 100%. FIGs. 6F-6G shows the results of Wt mice being administrated LPS followed with intranasal administration of either control CM (Ctr) or AKR1B8 CM (AKR) 30 min after LPS treatment. Lungs were collected after 9-hour LPS treatment and immediately after PI infusion. Pl-positive cell number and BAL MDA content were then determined. FIGs. 6H-6I show Wt mice being administrated LPS followed with intranasal administration of either control CM (Ctr) or AKR1B8 CM (AKR) 30 min after LPS treatment. Lungs were collected 2 hours after FITC-BSA infusion and 18 hours post LPS-treatment. FIG. 6J shows the effects of EV preparations containing AKR1 proteins on RSL-3-induced ferroptosis of HEK293 cells. 1B8, mouse AKR1B8; 1B1, human AKR1B1; 1C3, human ARK1C3; 1B10, human ARK1B10. FIG. 6K. Effects of liposome-encapsulated AKR1B10 on RSL-3-induced ferroptosis of HEK293 cells. The AKR1B10 protein was added before (+b) or post (+p) liposome formation. Data in FIGs. 6D-6K are presented as means±sem (One-way ANOVA for FIGS. 6E, 6J, 6K, n>3 biological replicates; two-tailed Student’s t-test for FIGs. 6D, 6F-6I; n>3). Each datum point in FIGS. 6D, 6F-6I represents one mouse. The experiment in FIGs. 6E, 6J, and 6K was repeated more than twice.

[0037] FIGs. 7A-7F show that the AKRlB8-deficiency exacerbates alveolar cell death and lung injury phenotypes. FIGs. 7A-7B show the results of the Wt control, Akrlb8- / -(Akr- / -), and Akrlb8- / -Fzd6Foxj1(DKO) mice being subjected to treatment and analyses as outlined in FIG. 4D. Representative images and quantification are shown. FIGs. 7C-7D show lung sections from the mice in FIG. 7 A stained with antibodies as indicated. FIGs. 7E-7F show the results of mice subjected to treatment and analysis as outlined in FIG. 1. Lung permeability and injury score are shown. Data in FIGs. 7B, 7C. 7E, and 7F are presented as means±sem (one-way ANOVA, n>4). Each datum point represents one mouse.

[0038] FIGs. 8A-8C show the effects of global Fzd6 KO on pulmonary inflammatory responses. FIG. 8A shows representative images of H& E-stained lung sections for FIG. IB. FIGs. 8B-8C show flow cytometry gating strategies for FIG. ID.

[0039] FIGs. 9A-9D show Fzd6 expression in Foxjl -positive cells. FIG. 9A shows a lung section from Foxjl-Cre Tdtomato mouse stained with an anti-FZD6 antibody and visualized for both FZD6 and Tdtomato under a confocal microscope. FIG. 9B shows expression of the ten Fzd genes in the Foxjl+cluster described in FIG. 2A. FIG. 9C shows that the loss o Fzd6 in Cdh5+endothelial cells did not affect pulmonary permeability upon LPS treatment. Data are presented as means±sem. Each datum point represents one mouse. FIG. 9D shows

[0040] 4

[0041] 578332772

[0042] Attorney Docket No. 047162-7558 WO 1 (02937)

[0043] individual Wt and Fzd6foxj 1 CKO UMAPs of CD45-negative lung cells.

[0044] FIGs. 10A-10H show that Fzd6Foxj1CKO suppresses ferroptosis in LPS-injured lungs. FIG. 10A shows representative images corresponding to the data in FIG. 4A. FIG. 10B shows the results of Wt mice being intratracheally administered LPS for different durations and perfused with PI immediately before sample collection. Pl-positive cells (red) and DAPI staining in lung sections are shown. FIG. 10C shows representative images of FIG. 4D. FIG.

[0045] 10D shows that ferrostatin- 1 reduces BAL MDA in the Wt mice following intratracheal administration of LPS. Data are presented as means±sem (p=0.005, two-tailed t-test). In FIGs. 10E-10F, Fzd6Foxj1CKO (Fzd6Fj1) and Wt mice were treated as in FIG. 10C.

[0046] Representative images for PI and activated Cas3 -positive cells are shown in FIG. 10E and their numbers were quantified from 5 independent sections per mouse lung and are shown in FIG. 10F. FIGs. 10G-10H show lung sections from a Wt mouse that was treated as in FIG.

[0047] 10C and stained with antibodies as indicated. Arrow heads in FIG. 10G denote cells double positive for CD326 and PI (dead epithelial cells), whereas arrows denote those double positive for CD31 and PI (dead endothelial cells). The arrow in FIG. 10H denotes a double positive cell for CD45 and PI. Data in FIGs. 10D, 10F are presented as means±sem (FIG. 10F, two-way ANOVA, n=5; FIG. 10D, two-tailed t-test, n=3). Each datum point represents one mouse.

[0048] FIGs. 11 A-l 1C shows the effects of ferroptosis inhibitors or Fzd6Foxj1CKO on MHV-59A infected lungs. FIGs. 11 A-l IB show BAL neutrophils in the lungs described in FIG. 5 analyzed by flow cytometry. Data are presented as means±sem. Each datum point represents one mouse. FIG. 11C. Three COVID-19-infected and one normal human lung sections w ere stained with anti-COVID19 spike protein and anti-4-HNE antibodies and examined by confocal microscopy.

[0049] FIGs. 12A-12J show AKR1 -containing conditioned media (CM) and EVs suppress ferroptosis. FIG. 12A shows Western blot detection of the AKR1B8 protein in CM used in FIGs. 6F-6I. FIG. 12B shows neutrophil abundance in the BALs of mice treated with control CM (Ctr) or AKR1B8 CM (CM) from mice described in FIGs. 6F-6I. Data are presented as means±sem. Each datum point represents one mouse. FIG. 12C shows a workflow of the preparation of EVs and EV-depleted CM (dEV) from CM of HEK293 cells expressing AKR1B8 or GFP.

[0050] FIG. 12D shows Western blot detection of AKR1B8 in EV and dEV preparations from cells expressing GFP or AKR1B8. The final volumes of these preparations were adjusted to the equivalent of CM concentrates used in cell-based assay shown in FIG. 6E. Five pL of EV

[0051] 5

[0052] 578332772

[0053] Attorney Docket No. 047162-7558 WO 1 (02937)

[0054] preparation and EV-depleted CM were loaded for the Western analysis. FIG. 12E shows the results of Wt mice being administered LPS followed by intranasal administration of EV or dEV preparations from cells expressing GFP or AKR1B8. Permeability was determined 18 hours post LPS treatment. The numbers denote the volumes in microliters administered to mice. FIG. 12F is a schematic representation depicting the process for preparing EVs using gradient ultracentrifugation and detecting ARK1B8 in the EV and non-EV fractions by Western blotting. FIG. 12G shows the effects of gradient ultracentrifugation fractions on RSL3-induced HEK293 cell death. FIG. 12H shows nanoparticle tracking analysis of EV preparations described in FIG. 12C. Representative graphs are shown. FIG. 121 shows Western blot detection of AKR1B8 and EV marker proteins in EVs precipitated with EV marker antibodies. FIG. 12J shows Western blot detection of AKR1 proteins in the EV preparations used in FIG. 6J, and dose-dependent protection of RSL-3-induced ferroptosis by AKR1B10 EV.

[0055] Data in FIGs. 12B, 12E, 12G, 12H, and 12J are presented as means±sem (One-way ANOVA for FIGs. 12E, 12G, and 12J; two-tailed Student’s t-test for FIGs. 12B, 12H). Each datum point in FIG. 12B represents one mouse and in FIGs. 12E, 12G, 12H, and 12J represents biological replicates. The experiment in FIGS. 12E, 12G, 12H, and 12J was repeated more than twice.

[0056] FIGs. 13A-13J shows that AKR1 associated EVs derived from BAL suppress ferroptotic lipid peroxidation and protect against LPS-induced lung injury through a noncell-autonomous mechanism. FIG. 13A shows the effects of EVs prepared from BAL of LPS-treated mice on LPS-induced pulmonary’ permeability, where “Mock” refers to mice treated with LPS only. FIGs. 13B-13E show Western blot detection of AKR1B8 in cells sorted from LPS-treated lungs from Wt, Akrlb8- / -and Fzd6Foxj1mice. FIG. 13F shows Western blot detection of AKR1B8 in EVs isolated from BALs from Wt, Akrlb8- / -and Fzd6Foxj1mice. FIG.

[0057] 13G shows a heatmap presentation of oxygenated PE species identified by mass spectrometry in mouse lung extracts that show upregulation by LPS treatment. FIG. 13H shows detection of LPS-upregulated oxygenated PE species in mouse lung extracts by mass spectrometry. Mice were instilled with LPS, control EV (Ctr), AKRlB8-containing EV (AKR) or administered with liproxstatin-1 (Lipl) as indicated. Samples were collected 10 hours after lung injury induction. FIG. 131 shows the effects of EVs isolated from HEK293 cells expressing AKR1B8 (AKR) or GFP (Ctr) on RSL3-induced death of cultured lung cells. FIG.

[0058] 13J show representative confocal images of RSL-3 treated MLE-12 cells stained with anti-4-HNE. Data in FIGs. 13A 13B, 13E, 13H, and 131 are presented as means±sem (One-way

[0059] 6

[0060] 578332772

[0061] Attorney Docket No. 047162-7558 WO 1 (02937)

[0062] ANOVA for FIG. 13A, Two-way ANOVA 13H; two-tailed Student’s t-test for FIGs. 13B, 13E, and 131). Each datum point in FIGs. 13 A, 13H represents one mouse and in FIGs. 13B.

[0063] 13E, and 131 represents biological replicates. The experiment in FIGs. 13A, 13B, 13E, and 131 was repeated more than twice.

[0064] FIGs. 14A-14B shows results characteristic of Akrlb8'1’ mice. FIG. 14A show s Western blot detection of AKR1B8 in BAL concentrates from Wt and Akrlb8 KO (Akr- / -) mice subjected to LPS-induced lung injury. FIG. 14B shows neutrophil abundance in the BALs of Wt, Akrlb8- / -(Akr- / -) or DKO mice described in FIG. 7C as determined by flow cytometry. Data in FIG. 14B are presented as means±sem. Each datum point represents one mouse.

[0065] FIG. 15 shows a schematic illustration of extracellular vesicles comprising AKR1B8 from ciliated epithelial cells suppressing ferroptosis of alveolar cells during lung inflammation. The illustration includes interactions among ciliated cells, FZD6, AKR1B8, lung inflammation, and ferroptosis.

[0066] DETAILED DESCRIPTION

[0067] The following disclosure provides many different embodiments, or examples, for implementing different features of the provided subject matter. Specific examples of components and arrangements are described below to simplify the present disclosure. These are merely examples and are not intending to be limiting. For example, the formation of a first feature over or on a second feature in the description that follows may comprise embodiments in which the first and second features are formed in direct contact, and may also comprise embodiments in which additional features may be formed between the first and second features, such that the first and second features may not be in direct contact.

[0068] In addition, the present disclosure may repeat reference numerals and / or letters in the various examples. This repetition is for the purpose of simplicity and clarity and does not in itself dictate a relationship between the various embodiments and / or configurations discussed.

[0069] Definitions

[0070] As used herein, each of the following terms has the meaning associated with it in this section. Generally, the nomenclature used herein and the laboratory procedures in animal pharmacology, pharmaceutical science, peptide chemistry, and organic chemistry are those

[0071] 7

[0072] 578332772

[0073] Attorney Docket No. 047162-7558 WO 1 (02937)

[0074] well-known and commonly employed in the art. It should be understood that the order of steps or order for performing certain actions is immaterial, so long as the present teachings remain operable. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting; information that is relevant to a section heading may occur within or outside of that particular section. All publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference.

[0075] In the application, where an element or component is said to be included in and / or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components and can be selected from a group consisting of two or more of the recited elements or components.

[0076] In the methods described herein, the acts can be carried out in any order, except when a temporal or operational sequence is explicitly recited. Furthermore, specified acts can be carried out concurrently unless explicit claim language recites that they be carried out separately. For example, a claimed act of doing X and a claimed act of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process.

[0077] In this document, the terms “a,” “an,” or “the,” are used to comprise one or more than one unless the context clearly dictates otherwise. The term “or” is used to refer to a nonexclusive “or” unless otherwise indicated. The statement “at least one of A and B” or “at least one of a or B” has the same meaning as “A, B, or A and B.” In some embodiments, “about” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.

[0078] As used herein, the term “aldo-keto reductase family 1 (AKR1) protein” refers to a member of the AKR superfamily of NAD(P)H-dependent oxidoreductase enzymes, specifically within family 1, which comprises cytosolic enzymes that catalyze the NADPH-dependent reduction of, and in some cases the reverse oxidation reactions, of a wide range of carbonyl-containing substrates, including aldehydes and ketones to their corresponding alcohols. These enzymes typically act on endogenous substrates such as steroids, prostaglandins, sugars, and lipid-derived aldehydes, as well as xenobiotic compounds.

[0079] An infection, disease, or disorder is “ameliorated” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is reduced.

[0080] 8

[0081] 578332772

[0082] Attorney Docket No. 047162-7558 WO 1 (02937)

[0083] As used herein, the term “composition” or “pharmaceutical composition” refers to at least one compound useful within the invention that is optionally mixed with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

[0084] As used in the specification and claims, the terms “comprises,” “comprising,” “containing,” “having,” and the like can have the meaning ascribed to them in U. S. patent law and can mean “includes,” “including,” and the like.

[0085] “Effective amount” or “therapeutically effective amount” are used interchangeably herein, and refer to an amount of a compound, formulation, material, or composition, as described herein effective to achieve a particular biological result or provides a therapeutic or prophylactic benefit.

[0086] As used herein, the term “ferroptosis” refers to a regulated form of cell death characterized by iron-dependent accumulation of lipid peroxides to lethal levels, leading to catastrophic membrane damage. Ferroptosis is a distinct, non-apoptotic, non-necrotic form of programmed cell death driven by iron-catalyzed lipid peroxidation, resulting in some instances from a failure of cellular antioxidant defenses, particularly the glutathioneglutathione peroxidase 4 (GPX4) system.

[0087] The term “human ortholog” is used herein with reference to a gene or protein in humans that is evolutionarily related to a gene or protein in another species by direct descent from a common ancestral gene.

[0088] The term “identity” as used herein refers to the sequence identity between two polymeric molecules particularly between two polypeptide molecules. When two amino acid sequences have the same residues at the same positions; e.g., if a position in each of two polypeptide molecules is occupied by an arginine, then they are identical at that position. The identity or extent to which two amino acid sequences have the same residues at the same positions in an alignment is often expressed as a percentage. The identity between two amino acid sequences is a direct function of the number of matching or identical positions; e.g., if half (e.g., five positions in a polymer ten amino acids in length) of the positions in two sequences are identical, the two sequences are 50% identical; if 90% of the positions (e.g., 9 of 10), are matched or identical, the two amino acids sequences are 90% identical.

[0089] The term “lipid peroxidation,” is used herein with reference to the oxidative degradation of lipids in which free radicals or reactive oxygen species extract hydrogen

[0090] 9

[0091] 578332772

[0092] Attorney Docket No. 047162-7558 WO 1 (02937)

[0093] atoms from unsaturated fatty acids, initiating a chain reaction that produces lipid hydroperoxides and secondary reactive aldehydes.

[0094] As used herein, the term '‘liposome” refers to a vesicle having an interior aqueous core surrounded by, and enclosed by, at least one lipid bilayer. Liposomes are typically spherical in shape but their shape and size may be controlled by their components, cargo, and preparation methods. In a liposome delivery product, the cargo (e.g., AKR1 family protein) is generally “contained” in liposomes. The word “contained” in this context includes both encapsulated and intercalated cargo. The term “encapsulated” refers to cargo within an aqueous space and “intercalated” refers to incorporation of the cargo within a bilayer.

[0095] Typically, water soluble cargos are contained in the aqueous compartment(s) and hydrophobic cargos are contained in the lipid bilayer(s) of the liposomes. Major types of liposomes include the multilamellar vesicle (MLV, with multiple lamellar phase lipid bilayers), the small unilamellar liposome vesicle (SUV, with one lipid bilayer), the large unilamellar vesicle (LUV), and the cochleate vesicle. Some liposomes are multivesicular, in which one vesicle contains one or more smaller vesicles.

[0096] As used herein, a “lipid bilayer” refers to a structure composed of two layers of lipid molecules organized in two sheets, functioning as a barrier. A lipid bilayer surrounds cells as a biological membrane, providing the cell membrane structure. Liposomes have a lipid bilayer that creates an inner aqueous compartment due to the hydrophilic heads and the hydrophobic tails of the lipids.

[0097] The term “modified” is used herein with reference to a changed state or structure of a molecule described herein. Molecules may be modified in many ways, including chemically, structurally, and functionally. Proteins may be modified through e.g., the introduction of fused amino acids.

[0098] As used herein, the term “PEGylated” is used with reference to a molecule, such as lipid or liposome, that has been covalently or noncovalently modified with polyethylene glycol (PEG) chains. The term “PEGylation” involves attaching one or more PEG chains to a molecule or surface, resulting in a “PEG shell” that alters how the substance behaves in biological systems.

[0099] As used herein, the term '‘pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function. Typically,

[0100] 10

[0101] 578332772

[0102] Attorney Docket No. 047162-7558 WO 1 (02937)

[0103] such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible w ith the activity of the compound useful within the invention, and are physiologically acceptable to the patient. Supplementary7active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention.

[0104] Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the disclosure are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0105] The terms “patient,” “subject,” or “individual” are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In a non-limiting embodiment, the patient, subject, or individual is a human.

[0106] As used herein, the terms “protein,” “peptide,” and “polypeptide” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least tw o amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both

[0107] 11

[0108] 578332772

[0109] Attorney Docket No. 047162-7558 WO 1 (02937)

[0110] short chains, which also commonly are referred to in the art as peptides, oligopeptides, and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. " Polypeptides" include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.

[0111] The term "pulmonary permeability” is used herein with reference to the degree to which molecules or particles can traverse lung tissues and membranes, including the airway epithelium, alveolar epithelium, interstitial space, and pulmonary vascular endothelium.

[0112] The term “therapeutic” as used herein means a treatment and / or prophylaxis. A therapeutic effect is obtained by suppression, remission, or eradication of a disease state.

[0113] To “treat” a disease or condition as the term is used herein, means to reduce the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject.

[0114] As used herein, the term “treatment” or “treating” is defined as the application or administration of a therapeutic agent, i.e., a compound of the disclosure (alone or in combination with another pharmaceutical agent), to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient (e.g., for diagnosis or ex vivo applications), who has a condition contemplated herein, a symptom of a condition contemplated herein or the potential to develop a condition contemplated herein, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect a condition contemplated herein, the symptoms of a condition contemplated herein or the potential to develop a condition contemplated herein. Such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics.

[0115] Unless specifically stated or obvious from context, the term “or,” as used herein, is understood to be inclusive.

[0116] Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise).

[0117] 12

[0118] 578332772

[0119] Attorney Docket No. 047162-7558 WO 1 (02937)

[0120] Detailed Description

[0121] Provided herein are methods of suppressing ferroptotic alveolar cell death and / or pulmonary damage caused by lung inflammation. Deficiency of the Wnt receptor Fzd6 reduces pulmonary permeability, lipid peroxidation, and ferroptotic alveolar cell death accompanied with an increase in alveolar number in pulmonary inflammation. In this regard, the present inventors have discovered that the aldo-keto reductase AKR1B8, produced by Foxj l+ciliated cells, protects alveolar cells from inflammation-induced ferroptotic death and injury, as demonstrated through the investigation of ciliated cell-specific knockout of the Wnt receptor FZD6. The FZD6 knockout increases Akrlb8 expression, reducing lipid peroxidation, alveolar cell death, and lung injury in response to lipopolysaccharide (LPS) or a coronavirus infection, effects that are not further altered by ferroptosis inhibitors.

[0122] Intratracheal administration of extracellular vesicles containing AKR1B8 protects alveolar cells from ferroptosis and mitigates lung injury, while AKR1B8 knockout exacerbates these phenotypes.

[0123] Aldo-keto reductase

[0124] In some embodiments, the compositions and methods described herein include an aldo-keto reductase family 1 (AKR1) protein. The AKR1 protein can be any AKR1 protein capable of catalyzing the NADPH-dependent reduction of carbonyl-containing compounds to their corresponding alcohols.

[0125] In some embodiments, the AKR1 protein can be an AKR1 member B protein (AKR1B) or an AKR1 member C protein (AKR1C). In some embodiments, the AKR1 protein is a human ortholog of the mouse AKR1B8 protein. More specifically, in some embodiments, the AKR1 protein is selected from an AKR1B1 protein, an AKR1B10 protein, an AKR1B15 protein, or an AKR1C3 protein.

[0126] In some embodiments, for example, the AKR1 protein includes the AKR1B1 protein having the sequence according to SEQ ID NO: 1 (MASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEV GVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIH WPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVE MILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPED PSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQ DMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF) (Accession No. P15121).

[0127] In some embodiments, for example, the AKR1 protein includes the AKR1B10 protein

[0128] 13

[0129] 578332772

[0130] Attorney Docket No. 047162-7558 WO 1 (02937)

[0131] having the sequence according to SEQ ID NO: 2 (MATFVELSTKAKMPIVGLGTWKSPLGKVKEAVKVAIDAGYRHIDCAYVYQNEHEV GEAIQEKIQEKAVKREDLFIVSKLWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHWP QGFKSGDDLFPKDDKGNAIGGKATFLDAWEAMEELVDEGLVKALGVSNFSHFQIEK LLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPEDP SLLEDPKIKEIAAKHKKTAAQVLIRFHIQRNVIVIPKSVTPARIVENIQVFDFKLSDEEM ATILSFNRNWRACNVLQSSHLEDYPFNAEY) (Accession No. 060218).

[0132] In some embodiments, for example, the AKR1 protein includes the AKR1B15 protein having the sequence according to SEQ ID NO: 3 (MATFVELSTKAKMPIVGLGTWRSLLGKVKEAVKVAIDAEYRHIDCAYFYENQHEV GEAIQEKIQEKAVMREDLFIVSKVWPTFFERPLVRKAFEKTLKDLKLSYLDVYLIHW PQGFKTGDDFFPKDDKGNMISGKGTFLDAWEAMEELVDEGLVKALGVSNFNHFQIE RLLNKPGLKYKPVTNQVECHPYLTQEKLIQYCHSKGITVTAYSPLGSPDRPWAKPED PSLLEDPKIKEIAAKHKKTTAQVLIRFHIQRNVTVIPKSMTPAHIVENIQVFDFKLSDEE MATILSFNRNWRAFDFKEFSHLEDFPFDAEY) (Accession No. C9JRZ8).

[0133] In some embodiments, for example, the AKR1 protein includes the AKR1C3 protein having the sequence according to SEQ ID NO: 4 (MDSKHQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYN NEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDL YLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRR QLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRW VDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQV FEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYSDEY) (Accession No. P42330).

[0134] In some embodiments, the AKR1 protein is modified as compared to the wild-type AKR1 protein. For example, in some embodiments, the modified AKR1 protein has an amino acid homology to the wild-type AKR1 protein of at least 50%, between 50% and 99%, between 50% and 98%, between 50% and 97%, between 50% and 96%, between 50% and 95%, between 50% and 90%, between 55% and 99%, between 60% and 99%, between 65% and 99%. between 70% and 99%, between 75% and 99%, between 80% and 99%, between 85% and 99%, or any combination, sub-combination, range, or sub-range thereof.

[0135] Additionally or alternatively, in some embodiments, the modified AKR1 protein is PEGylated (e.g., PEGylated AKR1B10), acetylated, or a combination thereof. In some embodiments, the AKR1 protein is fused with one or more amino acid sequences selected and / or configured for purification, identification, and / or stability. Suitable amino acid

[0136] 14

[0137] 578332772

[0138] Attorney Docket No. 047162-7558 WO 1 (02937)

[0139] sequences include, but are not limited to, histidine tag, HA-tag, human immunoglobulin Fc domain, other inert sequences, or a combination thereof.

[0140] Compositions for treating lung inflammation

[0141] In some embodiments, the compositions described herein include a liposome associated with an aldo-keto reductase family 1 (AKR1) protein as described above. In some embodiments, the AKR1 protein is encapsulated in the liposome. In some embodiments, the composition further includes a pharmaceutically acceptable carrier.

[0142] The liposome can include one or more lipids selected from phospholipids, diglycerides, dialiphatic glycolipids, single lipids such as sphingomyelin and glycosphingolipid, cholesterol and derivates thereof, and combinations thereof. As defined herein, phospholipids are amphiphilic agents having hydrophobic groups formed of long-chain alkyl chains, and a hydrophilic group containing a phosphate moiety. The group of phospholipids includes phosphatidic acid, phosphatidyl glycerols, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, phosphatidylserines, and mixtures thereof. The phospholipids may be chosen from hydrogenated egg yolk phosphatidylcholine (HEPC), soy phosphatidylcholine (SPC), egg yolk phosphatidylcholine (EYPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), hydrogenated soy phosphatidylcholine (HSPC), 1,2-dimyristoyl-sn-glycero-phophocholine (DMPC), l,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1.2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), l,2-dioleoyl-sn-glycero-3-phospho-rac-(l -glycerol) sodium salt (DOPG), l,2-dipalmitoyl-sn-glycero-3-phospho-rac-(l-glycerol) sodium salt (DPPG), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), l-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), l-palmitoyl-2-oleyol-sn-glycero-3-phospho-rac-(l-glycerol) sodium salt (POPG), N-(3-malimide-l-oxopropyl)-l,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE-mal), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2,-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), l,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), l,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), l,2-diphytanoyl-sn-glycero-3-phosphoethanolamine, monomethyl-phosphatidyl ethanolamine, dimethylphosphatidylethanolamine, l,2-dierucoyl-sn-glycero-3-phosphoethanolamine (DEPE), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (SOPE), l,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLOPC), l,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), and others and mixtures thereof. Other diacyl-phosphatidylcholine, diacyl-phosphatidylethanolamine,

[0143] 15

[0144] 578332772

[0145] Attorney Docket No. 047162-7558 WO 1 (02937)

[0146] and diacyl-phosphatidylserine phospholipids, sterol modified lipids, cationic lipids and zwitter lipids may also be used. In some embodiments, the acyl groups in these lipids are acyl groups derived from fatty acids having C10-C24 carbon chains (e.g., lauroyl, myristoyl, palmitoyl, stearoyl, or oleoyl).

[0147] Liposomes can also include one or more PEG-lipid conjugates. Non-limiting examples of PEG-lipid conjugates include l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [methoxy (poly ethylene glycol)-2000] sodium salt (mPEG2000-DSPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] sodium salt (PEG2000-DPPE), l,2-dimyristoyl-rac-glycero-3-methoxypoly ethylene glycol-2000 (PEG2000-DMG), distearoyl-rac-glycerol-PEG2000 (PEG2000-DSG),

[0148] methoxypoly ethyleneglycoloxy(2000)-N, N-ditetradecylacetami de (ALC-0159), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[amino(poly ethylene glycol)-2000] sodium salt (DOPE-PEGlOOO-amine), l,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] sodium salt (DGPE-PEG2000-amine), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(poly ethylene glycol)- 1000] sodium salt (DOPE-PEGIOOO-COOH), l,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(poly ethylene glycol)-2000] sodium salt (DOPE-PEG2000-COOH), and cholesterolpolyethylene glycol-600) (PEG600-Chol), PEGylated ceramides, PEGylated phosphatidic acids, PEGylated phosphatidylethanolamines, PEG} dated dialkylamines, PEGylated diacylglycerols, PEGylated dialkylglycerols, PEGylated glycerides, PEGylated sterols, and others, and mixtures thereof. In some embodiments, the polyethylene glycol chain will have an average molecular mass of 2000 atomic mass units. Other polymer conjugated lipid can also be used, for example, polyglycerol-modified, polyacrylamide-modified, polydimethylacry lamide-modified, polyvinylpyrrolidone-modified, hyaluronic acid-modified, heparin-modified, polysialic acid-modified, and the like.

[0149] Methods for making liposomes (including liposomes having one or more proteins associated with the liposome or encapsulated in the liposome) are know n in the art. In general, a suitable mixture of lipids can be dissolved in a solvent system (e g., a mixture of non-polar organic solvent(s), polar organic solvent(s), and optionally water), dried, and rehydrated in a buffer. One or more proteins may be present in the buffer or added to the buffer. The lipids, buffer, and protein (if present) are then subjected to one or more freezethaw cycles. See, for example, Koide, H. et al. “Easy preparation of a liposome-mediated protein delivery system by freeze-thawing a liposome-protein complex / ’ J Mater Chem B 10, 6768-6776 (2022); Xu, X., Costa, A. & Burgess, D. J. “Protein encapsulation in unilamellar

[0150] 16

[0151] 578332772

[0152] Attorney Docket No. 047162-7558 WO 1 (02937)

[0153] liposomes: high encapsulation efficiency and a novel technique to assess lipid-protein interaction / ’ Pharm Res 29, 1919-1931 (2012); and Zhang, Y. et al. " A netw ork of interactions enables CCM3 and STK24 to coordinate UNC13D-driven vesicle exocytosis in neutrophils.” Dev Cell l, 215-226 (2013), each of which is incorporated by reference in its entirety.

[0154] Methods for preparing, stabilizing, and delivering liposomal formulations.

[0155] In some embodiments, the AKR1 family protein is prepared in a highly stabilized aqueous liposomal vehicle for delivery' by inhalation, intratracheal administration, intravenous injection, or intranasal administration. In some embodiments, the liposomes may comprise one or more phospholipids selected from phosphatidylcholine (PC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), hydrogenated soy phosphatidylcholine (HSPC), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), dioleoylphosphatidylethanolamine (DOPE), sphingomyelin, and combinations thereof. In some embodiments, the phospholipid component is present at about 50-99 mol% of total lipid. In some embodiments, the formulation may further comprise cholesterol or another sterol in an amount of about 1-40 mol%, optionally about 5-30 mol%, to increase membrane rigidity' and reduce leakage during nebulization. In some embodiments, a PEGylated lipid such as DSPE-PEG2000 may be included at about 0.1-10 mol%, optionally about 0.5-5 mol%, to improve colloidal stability and reduce aggregation.

[0156] In some embodiments, the concentration of the protein generally ranges from 0.1 mg / mL to 50 mg / mL. In some embodiments, to maintain the native conformational state, the solution may be buffered to a specific target pH (typically pH 5.5 to 7.5) using biocompatible buffers such as sodium phosphate or histidine. In some embodiments, to prevent aggregation at the air-liquid interface, the formulation may incorporate non-ionic surfactants, such as Polysorbate 80 or Poloxamer 188, at concentrations between 0.01% and 0.5% (w / v).

[0157] Additionally, polyols like mannitol or disaccharides like trehalose may be added to provide tonicity adjustment and serve as cryoprotectants during any necessary’ freezing or drying stages.

[0158] In exemplary embodiments, the liposomal composition is comprised of a mixture of synthetic phospholipids and sterols as described above. In one embodiment, the lipid phase consists of DPPC and cholesterol in a molar ratio ranging from 70:30 to 50:50. In some embodiments, the lipids are dissolved in an organic solvent (e.g., ethanol or chloroform), which is then removed via rotary' evaporation to form a thin lipid film. This film is

[0159] 17

[0160] 578332772

[0161] Attorney Docket No. 047162-7558 WO 1 (02937)

[0162] subsequently hydrated with the protein-containing aqueous buffer. To achieve a uniform vesicle size distribution suitable for deep-lung deposition, the resulting suspension may be subjected to high-pressure extrusion through polycarbonate membranes with a pore size of e.g., 100 nm to 200 nm or processed via high-shear homogenization at controlled temperatures.

[0163] Compositions and methods for delivery of liposomal compositions by inhalation.

[0164] In some embodiments, a liposomal composition encapsulating an AKR1 family protein is prepared for inhalation delivery via nebulizer. In some embodiments, a nebulizable liposomal comprises an aqueous suspension of liposomes encapsulating the AKR1 family protein. In some embodiments, a nebulizable liposomal formulation comprises an aqueous suspension of preformed liposomes configured for aerosolization without prior drying. The liposomes may comprise a lipid bilayer formed from phospholipids selected from DPPC, DSPC, HSPC, phosphatidylcholine (PC), and combinations thereof, optionally in combination with phosphatidylglycerol (PG) or phosphatidylethanolamine (PE). In some embodiments, the phospholipid component is present at about 60-95 mol% of total lipid, and cholesterol is present at about 5-35 mol%, optionally about 10-30 mol%, to provide bilayer rigidity under shear conditions encountered during nebulization.

[0165] In some embodiments, the composition is specifically configured to withstand aerosol generation stresses and therefore is substantially free of solid-state excipients such as sugars or bulking agents in high concentrations. In some embodiments, the aqueous phase comprises an isotonic buffer, such as phosphate-buffered saline, citrate buffer, or histidine buffer, adjusted to a pH of about 6.0-7.4 and an osmolality of about 200-350 mOsm / kg. In some embodiments, Viscosity is maintained below about 5 cP to enable efficient nebulization.

[0166] In some embodiments, a method of preparation begins with the preparation of a highly stabilized aqueous phase containing the AKR1 family protein. In some embodiments, the AKR1 protein therapeutic protein is dissolved in an aqueous hydration medium at a concentration from about 0.01-200 mg / mL, about 0.1-100 mg / mL, about 0.5-100 mg / mL, about 1-50 mg / mL, or about 1-25 mg / ml. In some embodiments, the aqueous phase may comprise water for injection, saline, phosphate-buffered saline, citrate buffer, histidine buffer, or combinations thereof, optionally adjusted to a pH of about 5.0-8.0, preferably about 6.0-7.5. In some embodiments, the formulation may further comprise tonicity-adjusting or stabilizing excipients including sodium chloride, sucrose, trehalose, mannitol, glycine, histidine, or combinations thereof. In some embodiments, to maintain the protein's native

[0167] 18

[0168] 578332772

[0169] Attorney Docket No. 047162-7558 WO 1 (02937)

[0170] tertiary structure during the energy -intensive process of atomization, the buffer may include histidine or sodium phosphate (pH 5.5 to 7.5) supplemented with non-ionic surfactants, such as Poloxamer 188 or Polysorbate 80 at concentrations of 0.01% to 0.2% (w / v), which preferentially migrate to the droplet surface during aerosolization, shielding the protein-loaded liposomes from interfacial denaturation. Additionally, a saccharide matrix of trehalose or sucrose may be incorporated at a weight ratio of 2: 1 to 5: 1 (sugar: lipid) to act as a molecular spacer and cryoprotectant.

[0171] In some embodiments, the lipid phase is specifically engineered for high bilayer stiffness to prevent premature drug leakage. In this case, the composition may utilize high-transition temperature (Tm) phospholipids, such as distearoylphosphatidylcholine (DSPC; 1,2-distearoyl-sn-glycero-3-phosphocholine) or DPPC, in combination with a high molar percentage of cholesterol (30% to 50 mol%).

[0172] In some embodiments, the liposomes are prepared by thin-film hydration followed by extrusion, homogenization, or microfluidization to achieve a mean particle size of about 50-300 nm prior to nebulization. In some embodiments, the lipid film may be hydrated using an aqueous solution comprising the therapeutic agent at a temperature above the lipid phase transition temperature to form multilamellar vesicles. In some embodiments, the liposomes are prepared by dissolving the lipid components in an organic solvent comprising chloroform, ethanol, methanol, or combinations thereof, followed by removal of solvent under reduced pressure to form a thin lipid film. In some embodiments, the liposomal-protein compositions are formed by thin-film hydration followed by manual extrusion or reverse-phase evaporation, which minimizes exposure to heat and high-energy sonication. Thus, in some embodiments, the lipids are dissolved in an organic solvent, evaporated to form a thin film, and then hydrated with the protein-containing aqueous phase. In some embodiments, the formulation may optionally include PEGylated lipids at about 0.5-5 mol% to reduce aggregation during aerosolization. In some embodiments, the resulting vesicles may be downsized by sonication, extrusion through polycarbonate membranes, high-pressure homogenization, microfluidization, or combinations thereof to produce liposomes having an average diameter from about 50-500 nm, from about 80-200 nm. or from about 80-120 nm. In certain embodiments, unencapsulated protein may be removed by dialysis, tangential flow filtration, gel filtration chromatography, centrifugation, or combinations thereof.

[0173] To ensure the resulting liposomes fit within the fine aerosol droplets required e g., for deep-lung deposition, the suspension may be subjected to high-pressure extrusion through polycarbonate membranes with a pore size of 80 nm to 100 nm to ensure homogeneity and

[0174] 19

[0175] 578332772

[0176] Attorney Docket No. 047162-7558 WO 1 (02937)

[0177] stability'. This ensures a strictly uniform Z-average diameter and a low Poly dispersity- Index (PDI < 0.1), which is important for stable aerosol performance. In some embodiments, the formulations are optimized to produce amass median aerodynamic diameter (MMAD) (or droplet size) from about 1-5 pm or 1-3 pm to achieve deep-lung deposition

[0178] In some embodiments, the AKR1 protein may be actively loaded into preformed liposomes using a transmembrane ion gradient or pH gradient. Representative loading gradients include ammonium sulfate, citrate, phosphate, or calcium acetate gradients. The liposomal suspension may subsequently be sterilized by filtration through a membrane having a pore size of about 0.22 pm where compatible with vesicle size and formulation properties. In some embodiments, the total lipid concentration of the nebulizable suspension is about 1-200 mg / mL, optionally about 5-100 mg / mL.

[0179] The nebulizable formulation may be configured to maintain encapsulation of at least about 50%, optionally at least about 70-90%, of the therapeutic agent following aerosolization. In certain embodiments, the formulation possesses a viscosity below about 5 cP and an osmolality of about 200-400 mOsm / kg to facilitate efficient nebulization and pulmonary tolerability. The formulation may be packaged in unit-dose ampules, vials, cartridges, or reservoirs suitable for use with a nebulizer device. In preferred embodiments, the nebulizer comprises a vibrating mesh nebulizer configured to generate aerosol droplets having a mass median aerodynamic diameter (MMAD) of about 1-5 pm. optionally about 2-4 pm, suitable for delivery to the lower respiratory tract and alveolar regions of the lung.

[0180] In some embodiments, the inhalable liposome composition comprises (a) an AKR1 protein encapsulated within a lipid vesicle; (b) a lipid bilayer comprising a phospholipid having a phase transition temperature (Tm) greater than 40°C and cholesterol in an amount from about 40 mol% to about 50 mol% of the total lipid content; (c) a non-ionic surfactant present in an amount from about 0.01% to about 0.5% (w / v) of the composition. In some embodiments, the lipid vesicles have a Z-average diameter of 80 nm to 120 nm and a poly dispersity- index (PDI) of less than 0.15. In some embodiments, the composition further comprises a saccharide cryoprotectant selected from trehalose or sucrose, wherein the weight ratio of saccharide to total lipid is between 2:1 and 5:1. In some embodiments, the composition, when aerosolized via a vibrating mesh nebulizer, produces an aerosol having a mass median aerodynamic diameter (MMAD) of 1.0 pm to 3.0 pm.

[0181] In some embodiments, the method of administering the nebulizable composition comprises aerosolizing the liposomal suspension using a nebulizer and administering the aerosol to a subject by oral inhalation. In certain embodiments, the subject inhales the aerosol

[0182] 20

[0183] 578332772

[0184] Attorney Docket No. 047162-7558 WO 1 (02937)

[0185] through a mouthpiece, facemask, endotracheal tube, tracheostomy tube, or combinations thereof.

[0186] In some embodiments, the nebulizer for administering the inhalable liposome composition in the form of an aerosol is a vibrating mesh nebulizer, such as the Lamira® Nebulizer System. This method utilizes a high-frequency (approx. 100-130 kHz) vibrating piezo-element to push the liquid through a precision-engineered mesh containing thousands of tapered apertures (typically 2-4 pm in diameter). In some embodiments, the nebulizer is a jet nebulizer. In some embodiments, the nebulizer generates an aerosol with a high fine particle Fraction (FPF) comprising droplets small enough (e.g., 1-5 pm) to reach the deep lung. In some embodiments, the nebulizer is chosen (e.g., vibrating mesh nebulizer) on the basis of its ability to generate a precision aerosol without significant heating or recycling of the drug reservoir. In some embodiments, the resulting aerosol bolus is characterized by a high Fine Particle Fraction (FPF), with more than 60% of the droplets falling within the respirable range.

[0187] The administered dose may range from about 0.01 mg to 1000 mg therapeutic agent per treatment session, depending on the indication and potency of the agent. Administration may occur once or multiple times daily, weekly, or according to a sustained-release dosing regimen. In some embodiments, pulmonary7administration of the nebulized liposomal formulation provides prolonged residence of the therapeutic agent in lung tissue, sustained release, reduced systemic toxicity, improved bioavailability, enhanced uptake into pulmonary epithelium or alveolar macrophages, and protection of labile biologies from degradation during delivery7.

[0188] Once deposited on the lung's epithelial surface, the liposomes act as a depot, slowly releasing the protein cargo over time. This targeted delivery can achieve high local concentrations in the lung while keeping systemic blood levels low to avoid kidney and ear toxicity7. In some embodiments, the resulting aerosol may7be characterized using a Next Generation Impactor (NGI) to verify that the Mass Median Aerodynamic Diameter (MMAD) remains between 1.0 pm and 4.0 pm, with a Fine Particle Fraction (FPF) exceeding 60%. In certain embodiments, the method includes a post-nebulization stability assessment, where the collected aerosol is analyzed via Size-Exclusion Chromatography (SEC) and encapsulation efficiency tests to confirm that the protein remains biologically active and sequestered within the liposomal carrier throughout the delivery7process.

[0189] In some embodiments, the liposomal composition comprises a dry powder inhaler (DPI) composition comprising spray-dried or lyophilized liposomal particles containing an

[0190] 21

[0191] 578332772

[0192] Attorney Docket No. 047162-7558 WO 1 (02937)

[0193] AKR.1 protein for pulmonary administration. The primary distinction between nebulized liposomal compositions and dry powder inhaler (DPI) liposomal compositions is that nebulized liposomal compositions are typically administered as aqueous dispersions of preformed liposomes, whereas DPI systems are generally administered as dry particles containing liposomes, proliposomes, or liposome precursors. Dry powder liposomal formulations are engineered primarily for aerosolization as solid respirable particles. The liposomes may either remain intact in dried form or exist as proliposomes that generate liposomes after contacting pulmonary fluids.

[0194] In some embodiments, the DPI composition is processed via spray drying. In some embodiments, a liquid feed is atomized through a two-fluid nozzle into a drying chamber where it encounters a heated gas stream (typically nitrogen). The inlet temperature is strictly controlled (usually 60°C to 100°C) to ensure rapid solvent evaporation without exceeding the protein’s thermal denaturation threshold. The process parameters are tuned to produce “large porous particles’’ with a geometric diameter of 5-10 pm but a low mass density', resulting in an aerodynamic diameter of 1-3 pm, optimized for gravitational sedimentation in alveolar spaces.

[0195] In some embodiments, the dry powder inhaler (DPI) composition comprises liposomal or proliposomal particles prepared by dehydration of a lipid-containing dispersion in the presence of solid-state stabilizing excipients. In some embodiments, the lipid component may comprise phospholipids selected from DPPC, DSPC, HSPC. and combinations thereof, optionally' in combination with cholesterol at about 5-30 mol% and PEG-lipid at about 0.1-5 mol%.

[0196] In contrast to nebulizable systems, the DPI formulation further comprises a solid matrix excipient system present at a lipid: excipient weight ratio of about 1: 1 to 1:20. Suitable excipients include lactose monohydrate, trehalose, sucrose, mannitol, glycine, and leucine, wherein sugars function as membrane protectants during dehydration and leucine functions as an aerosol dispersion enhancer. In certain embodiments, trehalose or sucrose is present at a concentration sufficient to form an amorphous glass matrix encapsulating liposomal structures during drying.

[0197] In some embodiments, the AKR1 protein is dissolved in an aqueous hydration medium at a concentration of about 0.01-200 mg / mL, optionally about 0.1-50 mg / mL. In some embodiments, the liposomal dispersion is prepared by thin-film hydration, ethanol injection, or microfluidic mixing, followed by size reduction to a mean vesicle diameter of about 50-300 nm prior to drying. The dispersion is then converted into a dry powder by spray

[0198] 22

[0199] 578332772

[0200] Attorney Docket No. 047162-7558 WO 1 (02937)

[0201] drying, spray freeze drying, or lyophilization under conditions that maintain outlet temperatures below about 90°C. In some embodiments, spray drying may be conducted using an inlet temperature of about 50-180°C and an outlet temperature of about 30-90°C sufficient to produce respirable particles while preserving liposome integrity and therapeutic activity. The resulting dry powder particles may be engineered to possess a mass median aerodynamic diameter (MMAD) of about 1-10 pm, optionally about 1-5 pm, and a low tapped density, optionally below about 0.4 g / cm3, to promote deep lung deposition.

[0202] The suspension may further comprise one or more stabilizing excipients selected from lactose, trehalose, sucrose, mannitol, leucine, glycine, histidine, or combinations thereof. In certain embodiments, the excipient is present at a lipid: excipient weight ratio of about 1:0.5 to 1:20, optionally about 1:1 to 1:10.

[0203] In some embodiments, the liposomes are not fully retained in intact form in the dry state but instead exist as proliposomal structures that reconstitute into vesicles upon contact with pulmonary7fluid following inhalation. In some embodiments, the formulation may be blended with carrier particles such as lactose for capsule or blister-based DPI devices. In some embodiments, administration is performed using a passive or active dry powder inhaler device, wherein inhalation of airflow disperses the powder into respirable particles for pulmonary' deposition. In certain embodiments, the composition exhibits a fine particle fraction (FPF) of at least about 20%. optionally at least about 40%, and maintains encapsulation of at least about 50-90% of the therapeutic agent following aerosolization.

[0204] In some embodiments, methods of delivering the dry powder composition to the respiratory tract of a subject may be carried out using a passive or active dry powder inhaler device. In some embodiments, the composition is administered orally by inhalation such that the aerosolized particles are deposited within the conducting airways, bronchioles, and / or alveolar regions of the lung. The administered dose may range from about 0.01 mg to 500 mg total powder per administration, depending on the therapeutic agent and indication. In certain embodiments, administration is performed one or more times daily, weekly, or according to a sustained-release dosing regimen. The liposomal DPI formulations may provide prolonged pulmonary residence, sustained release of encapsulated therapeutic agent, reduced systemic exposure, enhanced bioavailability, protection of labile biologies from degradation, and improved tolerability' relative to nonliposomal formulations.

[0205] In some embodiments, the integrity' of the delivered protein may be verified post-aerosolization using analytical techniques such as Size-Exclusion Chromatography (SEC) to detect aggregates and Circular Dichroism (CD) spectroscopy to confirm the preservation of

[0206] 23

[0207] 578332772

[0208] Attorney Docket No. 047162-7558 WO 1 (02937)

[0209] secondary structures. The aerodynamic performance of the aerosol is quantified using a Next Generation Impactor (NGI) or an Andersen Cascade Impactor (ACI). These devices simulate the human respiratory tract, allowing for the measurement of the Mass Median Aerodynamic Diameter (MMAD) and the determination of the total dose delivered to the "lower airway" stages of the apparatus.

[0210] Compositions and methods for intratracheal administration of liposomal compositions.

[0211] In some embodiments, a liposomal formulation for intratracheal administration comprises a sterile aqueous suspension of liposomes configured for direct deposition into the tracheobronchial tree without aerosolization. While aerosol formulations prioritize droplet size, intratracheal (IT) administration allows for the delivery of higher protein payloads in smaller liquid volumes to avoid "drowning" the lung segment. In this case, the protein concentration is typically increased to 10 mg / mL to 100 mg / mL.

[0212] In some embodiments, the liposomes may comprise phospholipids selected from DPPC, DSPC, HSPC, phosphatidylcholine (PC), and phosphatidylglycerol (PG), optionally in combination with cholesterol at about 5-40 mol% to enhance membrane stability in airway fluids. PEGylated lipids may be present at about 0.1-5 mol% in certain embodiments, although are not required.

[0213] Unlike nebulized or DPI formulations, the intratracheal formulation is not constrained by aerosol generation requirements and therefore may include higher viscosity or mucointeractive excipients. In some embodiments, the formulation further comprises viscosity-modifying or retention-enhancing agents such as hyaluronic acid, chitosan derivatives, or cellulose-based polymers at low concentrations sufficient to increase mucosal residence time without impairing flowability. The aqueous phase may comprise isotonic buffered saline at pH about 6.5-7.5.

[0214] In some embodiments, the buffering system is strictly iso-osmolar (280-300 mOsm / L) to prevent osmotic shock to the delicate alveolar epithelium. In this context, the inclusion of e.g., DPPC is helpful, as it acts as a "spreading agent," utilizing the lung’s natural surfactant pathways to distribute the bolus more evenly across the pulmonary surface.

[0215] In some embodiments, the liposomes are prepared by thin-film hydration, reversephase evaporation, or ethanol injection, followed by size adjustment to a mean diameter of about 100-500 nm, optionally up to about 1 pm in certain depot applications. The therapeutic agent may be encapsulated at concentrations of about 0.01-100 mg / mL depending on

[0216] 24

[0217] 578332772

[0218] Attorney Docket No. 047162-7558 WO 1 (02937)

[0219] potency and dosing requirements. Unencapsulated drug may be removed by filtration, dialysis, or centrifugation.

[0220] In some embodiments, the lipid vesicles may be engineered to be smaller and more flexible to navigate the mucosal lining. Specifically, the extrusion process may be refined to produce liposomes with a Poly dispersity Index (PDI) of <0.15 and a mean diameter of 80 nm to 120 nm. In some embodiments, the membrane composition may include “edge activators” (e.g, small amounts of sodium cholate or Polysorbate 80) to create deformable liposomes (transfersomes). These flexible vesicles are more adept at penetrating the surfactant layer and reaching the underlying epithelial cells compared to rigid, high-cholesterol vesicles.

[0221] In some embodiments, an intratracheal liposome composition for localized pulmonary delivery comprises: (a) an AKR1 protein at a concentration of 10 mg / mL to 100 mg / mL; (b) lipid vesicles having a Z-average diameter from about 100 nm to about 200 nm; and (c) an iso-osmolar aqueous vehicle having an osmolality' of 280 mOsm / L to 320 mOsm / L. In some embodiments, the lipid vesicles comprise a phospholipid and cholesterol, wherein the cholesterol is present in an amount from about 20 mol% to about 35 mol% of the total lipid content. In some embodiments, the composition further comprises a mucoadhesive agent selected from the group consisting of hyaluronic acid, chitosan, and carboxymethylcellulose. In some embodiments, a method of treating a subject having lung inflammation comprises administering the intratracheal formulation via micro-aerosolization at the tracheal bifurcation, wherein the total administration volume is less than 5.0 mL.

[0222] In some embodiments, administration is performed by direct instillation into the trachea using an endotracheal tube, tracheostomy tube, catheter, or bronchoscope. The formulation may be delivered as a bolus or controlled infusion in volumes ranging from about 0.1 mL to 50 mL depending on subject size. Upon administration, the liposomal suspension disperses along the tracheal and bronchial surfaces, forming a localized pulmonary depot that provides sustained release of the therapeutic agent. This route results in high local pulmonary exposure with reduced dependence on aerosol particle formation and minimal loss due to exhalation or device inefficiency.

[0223] In some embodiments, liposomal compositions for IT delivery are administered by direct liquid delivery. In an embodiment, the liquid delivery is carried out by bolus instillation. In an embodiment, the liposomal composition is delivered as a liquid formulation by bolus instillation through an endotracheal tube or a catheter positioned at the tracheal bifurcation (carina). In some embodiments, a suitable volume of the liquid liposomal suspension (e.g., 5-100 pL for rat; 1-5 mL for a human) is discharged rapidly from a syringe

[0224] 25

[0225] 578332772

[0226] Attorney Docket No. 047162-7558 WO 1 (02937)

[0227] or catheter as a continuous stream. In this case, the liquid relies on gravity' and the subject's own breathing to “wick” the formulation into the lower lung lobes. This simple approach, requiring no specialized equipment beyond a catheter, tends to result in a more heterogeneous distribution, where the liquid pools in the dependent (lower) areas of the lungs.

[0228] In some embodiments, liposomal compositions for IT delivery' are delivered by micro-aerosolization. In some embodiments, micro-aerosolization is carried out using a high-pressure cannula with an atomizing tip. In an embodiment, micro-aerosolization is carried out by micro-spraying using a device such as a micro-sprayer (e.g., a Penn-Century Microsprayer®) to atomize the liquid at the point of delivery', generating a “cloud” of liquid directly at the tip of a narrow cannula inserted into the trachea. The liquid is pushed through a high-pressure micro-nozzle at the tip of a long, thin cannula inserted into the trachea. This converts the liquid bolus into a fine, high-velocity “plume” or “cloud” of micro-droplets. Because the liquid is already atomized before it hits the lung surface, it achieves a much more homogeneous (uniform) distribution across all lung lobes, including the periphery7. This ensures that the protein-loaded liposomes are distributed deeper into the distal lung regions (bronchioles and alveoli) than a simple liquid bolus would allow. In some embodiments, this achieves higher therapeutic efficacy and more uniform pulmonary distribution, and reduces localized toxicity7, as it prevents the “pooling” seen with bolus instillation. In some embodiments, a method of treating a subject having lung inflammation comprises administering the intratracheal formulation via micro-aerosolization at the tracheal bifurcation, wherein the total administration volume is less than 5.0 mL.

[0229] In some embodiments, to optimize the residence time of the protein in the lungs, the composition may include spreading or retention enhancers, such as viscosity modifiers or mucoadhesives. Thus, in some embodiments, small percentages (0.1% to 1.0%) of high-molecular-weight hyaluronic acid or pegylated lipids (PEG-DSPE) are added to the formulation. These components can reduce the rate of clearance by' the mucociliary' escalator and protect the liposomes from being immediately sequestered by alveolar macrophages, thereby extending the therapeutic window of the protein.

[0230] In some embodiments, the efficiency of the IT delivery (post-administration) may be verified by analyzing the BAL fluid for protein concentration and using fluorescently labeled liposomes to map the “lobar distribution.” This ensures that the method provides uniform coverage across all lung lobes, an important metric when providing localized pulmonary therapy.

[0231] 26

[0232] 578332772

[0233] Attorney Docket No. 047162-7558 WO 1 (02937)

[0234] Compositions and methods for intranasal administration.

[0235] In some embodiments, an intranasal liposomal formulation comprises an aqueous suspension of protein-containing liposomes configured for localized nasal and upper airway delivery while substantially minimizing transport of the therapeutic agent to the olfactory bulb or central nervous system. In some embodiments, the composition comprises one or more phospholipids selected from phosphatidylcholine (PC), hydrogenated soy phosphatidylcholine (HSPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), phosphatidylglycerol (PG), and combinations thereof. In some embodiments,, the phospholipid component is present at about 60-98 mol% of total lipid. Cholesterol or another sterol may be included at about 2-35 mol%, optionally about 5-25 mol%, to increase bilayer rigidity and reduce premature leakage of encapsulated protein. In some embodiments, the composition is substantially non-cationic and excludes strongly muco-penetrating surface modifications in order to reduce uptake into olfactory neuronal pathways.

[0236] In some embodiments, the AKR1 protein is present from about 0.01 mg / ml to about 100 mg / mL, optionally from about 0.1 mg / mL to about 25 mg / mL. In some embodiments, the aqueous phase comprise isotonic saline, phosphate buffer, citrate buffer, histidine buffer, or combinations thereof, adjusted to a pH from about 5.5 to about 7.0, optionally from about 6.0 to about 6.8. In some embodiments, the composition may further comprise viscosityenhancing or muco-retentive excipients selected from hydroxypropyl methylcellulose, carboxymethylcellulose, hyaluronic acid, poloxamers, alginate, or combinations thereof, generally at concentrations of about 0.01-2 wt%, to promote retention within the anterior nasal cavity' while reducing posterior migration toward the olfactory' epithelium.

[0237] In some embodiments,, the liposomes are prepared by dissolving lipid components in an organic solvent comprising ethanol, chloroform, methanol, or mixtures thereof, followed by solvent removal to form a lipid film. In some embodiments, the lipid film may then be hydrated using an aqueous protein solution at a temperature above the lipid transition temperature to produce multilamellar vesicles. In some embodiments, the vesicles are subsequently be downsized by extrusion, homogenization, or microfluidization to produce liposomes having a mean diameter of from about 150 nm to about 1000 nm, optionally from about 200 nm to about 600 nm. In certain embodiments, a relatively larger particle size is selected to reduce neuronal uptake and trans-olfactory transport while favoring retention within nasal mucus. In some embodiments, PEGylated lipids may be included. In some embodiments, the PEGylated lipids are present at low levels, optionally less than about 2

[0238] 27

[0239] 578332772

[0240] Attorney Docket No. 047162-7558 WO 1 (02937)

[0241] mol%, or excluded entirely to reduce mucus penetration and epithelial translocation.

[0242] In some embodiments, the composition may further comprise tonicity-adjusting agents or protein stabilizers including sucrose, trehalose, mannitol, glycine, or histidine. In certain embodiments, the composition is configured to exhibit limited penetration across nasal epithelium and preferentially retain the therapeutic protein within the nasal cavity or upper respiratory mucosa. In some embodiments, the liposomal suspension may possess a viscosity of about 10-500 cP, optionally about 20-200 cP, sufficient to reduce drainage into posterior nasal regions associated with olfactory transport pathways. In some embodiments, the final composition may be sterilized by aseptic processing or filtration where compatible with liposome size.

[0243] In some embodiments, the method of administering the composition comprises intranasally administering the liposomal composition to the subject using a metered nasal spray device, pump sprayer, dropper, nebulizer, or unit-dose applicator configured to deliver the composition primarily to the anterior and respiratory regions of the nasal cavity. In some embodiments, the composition is administered at an angle and spray plume geometry’ selected to reduce deposition in the superior posterior nasal cavity containing olfactory epithelium. In some embodiments, the administered dose may comprise from about 10 pL to about 500 pL per nostril, optionally from about 25 pL to about 200 pL per nostril, containing about 0.001-100 mg of AKR1 protein per administration.

[0244] In some embodiments, administration is performed one or more times daily or according to a prophylactic or therapeutic dosing regimen. In some embodiments, following intranasal delivery, the liposomal composition adheres to nasal mucosa and releases the encapsulated protein locally or regionally within the upper respiratory' tract while substantially limiting systemic absorption and minimizing transport to brain tissue through olfactory or trigeminal pathways. The composition may thereby provide localized antiinflammatory', antiviral, immunomodulatory', or mucosal therapeutic activity with reduced central nervous system exposure.

[0245] Additional disclosures describing liposomal compositions and methods for administering liposome compositions are described in U. S. Pat. Nos. 7,384,649, 10,258,570, 11,534,399, and U. S. Pat. Appl. Publ. Nos. 2005 / 0025822, 2006 / 0002992, 2010 / 0310660, and 2017 / 0035753, the disclosures of which are expressly incorporated by reference in their entirety herein.

[0246] Compositions and methods for intravenous administration.

[0247] 28

[0248] 578332772

[0249] Attorney Docket No. 047162-7558 WO 1 (02937)

[0250] In some embodiments, the liposomal compositions are delivered by intravenous administration. In some embodiments, liposomal compositions for IV administration comprise one or more PEGylated lipids, such as DSPE-PEG2000. While PEG may be used in nebulization to prevent vesicle aggregation, in IV delivery, it is used to create a “stealth” layer in the form of a hydrophilic coating creating a steric barrier preventing e.g., the adsorption of serum opsonins, thereby shielding the liposomes from detection by macrophages. In some embodiments, the molar percentage of PEG-lipids is from about 5- 10 mol%. In some embodiments, the liposome composition comprises: (a) an AKR1 protein; (b) a neutral phospholipid; (b) a sterol; and (d) a PEGylated lipid, wherein the PEGylated lipid is present in an amount ranging from 5 mol% to 10 mol% relative to the total lipid content. In some embodiments, the lipid composition comprises a lipid bilayer comprising a neutral phospholipid, cholesterol, and a PEGylated lipid. In some embodiments, the lipid vesicles have a Z-av erage diameter from about 80 nm to about 110 nm and a PDI of less than 0.1. In some embodiments, the phospholipid is DSPC or HSPC and the cholesterol is present at 30 mol% to 45 mol%. such that the lipid bilayer remains in a solid-ordered phase at 37°C. In some embodiments, the composition is characterized by a Sterility Assurance Level (SAL) of 10'6and is substantially free of unencapsulated protein.

[0251] In some embodiments, whereas pulmonary compositions may utilize DPPC for its lung-surfactant compatibility, IV compositions may include DSPC or Hydrogenated Soy PC (HSPC) because their higher phase transition temperatures (Tmabout 55°C) ensure the bilayer remains in a rigid, “solid-ordered” state at the internal body temperature of 37°C, preventing premature burst release of the protein. In some embodiments, the high-pressure extrusion step is modified to ensure a diameter from about 80 nm -120 nm and / or the polydispersity index (PDI) is chosen to be less than about 0.1 to ensure predictable pharmacokinetics. In some embodiments, unencapsulated protein and organic solvent traces are removed by tangential flow filtration (TFF) or dialysis. In some embodiments, the liposomes in a composition for IV administration comprise a Z-av erage diameter from about 80-120 nm, a zeta potential from about -5 mV to -15 mV, and a lipid-to-protein ratio of from about 20:1 to 100:1.

[0252] Additionally, in certain embodiments, the liposome composition is stored in a cryoprotectant buffer (e.g., 10% sucrose) to prevent membrane rupture during freeze-thaw cycles required for clinical distribution.

[0253] Methods of treating, ameliorating, and / or preventing lung inflammation

[0254] In one aspect, the present disclosure provides a method for treating a subject having

[0255] 29

[0256] 578332772

[0257] Attorney Docket No. 047162-7558 WO 1 (02937)

[0258] lung inflammation, the method comprising administering to a subject in need thereof a liposomal composition described herein.

[0259] The methods disclosed herein may be used to treat a subject with lung inflammation or inflammatory lung conditions or diseases. Exemplary inflammatory lung conditions and diseases include, but are not limited to, acute lung inflammation; lung inflammation caused by acute respiratory distress syndrome (ARDS), a bacterial infection, bacterial infection-related pneumonia, sepsis-associated lung injury, a viral infection or viral pneumonia, an ischemia-reperfusion injury, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, cystic fibrosis, and / or asthma; ventilator-associated pneumonia (VAP); pulmonary fibrosis; or any other suitable lung inflammation-related disease involving ferroptotic alveolar cell death. Viral infections include, but are not limited to, respiratory syncytial virus (RSV) infection, coronavirus (e.g, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle Eastern respiratory' syndrome coronavirus (MERS-CoV)), Influenza virus infection (viral pneumonia), Adenoviral infection, Parainfluenza virus infection, Rhinovirus infection, or a combination thereof. Bacterial infections include, but are not limited to, Streptococcus pneumoniae infection, Haemophilus influenzae infection. Staphylococcus aureus infection, Klebsiella pneumoniae infection, Pseudomona aeruginosa infection, or a combination thereof. For example, in some embodiments, the method includes administering a composition as described herein according to one or more of the embodiments disclosed herein to treat a subject having severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

[0260] In some embodiments, a method of treating a subject having lung inflammation includes administering to a subject in need thereof a composition including a liposome and an aldo-keto reductase family 1 (AKR1) protein associated with the liposome. The administration may be through any suitable route of administration, such as, but not limited to, intranasal, intratracheal, intravenous (IV), inhalation, or a combination thereof.

[0261] In some embodiments, administering the composition to the subject reduces pulmonary damage caused by the lung inflammation, reduces ferroptosis, reduces ferroptotic alveolar cell death, reduces pulmonary permeability / edema, reduces lipid peroxidation, clears pulmonary opacities on radiography, restores blood oxygenation reduction, reverses hypoxemia, or a combination thereof. In one embodiment, for example, the method includes administering the composition to a subject having acute lung inflammation, where the administering of the composition reduces or eliminates pulmonary damage caused by the acute lung inflammation. Additionally or alternatively, in some embodiments, administering

[0262] 30

[0263] 578332772

[0264] Attorney Docket No. 047162-7558 WO 1 (02937)

[0265] the composition to the subject reduces edema, clears pulmonary opacities on radiography, restores blood oxygenation reduction, reverses hypoxemia, reverses or reduces ischemiareperfusion injury, reverses or reduces chronic obstructive pulmonary disease (COPD), reverses or retards pulmonary fibrosis, reverses or retards cystic fibrosis, reverses asthma, or a combination thereof. As such, in some embodiments, in addition to treating the lung inflammation, the methods disclosed herein also treat the underlying condition causing the lung inflammation.

[0266] Pharmaceutical Compositions and Formulations

[0267] Also provided are compositions including the liposomal composition of the present invention for administration, including pharmaceutical compositions and formulations, such as unit dose form compositions including the number of liposomal particles for administration in a given dose or fraction thereof. The pharmaceutical compositions and formulations generally include one or more optional pharmaceutically acceptable carrier or excipient. In some embodiments, the composition includes at least one additional therapeutic agent. The terms "pharmaceutical formulation” and "pharmaceutical composition” are used interchangeably with reference to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. A '“pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative. In some aspects, the choice of carrier is determined in part by the particular cell and / or by the method of administration. Accordingly, there are a variety of suitable formulations. For example, the pharmaceutical composition can contain preservatives. Suitable preservatives may include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride. In some aspects, a mixture of two or more preservatives is used. The preservative or mixtures thereof are ty pically present in an amount of about 0.0001% to about 2% by weight of the total composition. Carriers are described, e.g., by Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium

[0268] 31

[0269] 578332772

[0270] Attorney Docket No. 047162-7558 WO 1 (02937)

[0271] chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG).

[0272] Buffering agents in some aspects are included in the compositions. Suitable buffering agents include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts. In some aspects, a mixture of two or more buffering agents is used. The buffering agent or mixtures thereof are typically present in an amount of about 0.001% to about 4% by weight of the total composition. Methods for preparing administrable pharmaceutical compositions are known. Exemplary methods are described in more detail in, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).

[0273] The formulations can include aqueous solutions. The formulation or composition may also contain more than one active ingredient useful for the particular indication, disease, or condition being treated with the cells, preferably those with activities complementary to the cells, where the respective activities do not adversely affect one another. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended. Thus, in some embodiments, the pharmaceutical composition further includes other pharmaceutically active cardiovascular agents or drugs. The pharmaceutical composition contains the AKR1 protein in amounts effective to treat or prevent the inflammatory disease or condition, such as a therapeutically effective or prophylactically effective amount.

[0274] Therapeutic or prophylactic efficacy in some embodiments is monitored by periodic assessment of treated subjects. The desired dosage can be delivered by a single bolus administration of the cells, by multiple bolus administrations of the cells, or by continuous infusion administration of the liposomal composition.

[0275] Formulations include those for intravenous, pulmonary, inhalation, intratracheal, and intranasal administration. Compositions in some embodiments are provided as aerosolized preparations. Compositions in some embodiments are provided as sterile liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions, or dispersions which may in some

[0276] 32

[0277] 578332772

[0278] Attorney Docket No. 047162-7558 WO 1 (02937)

[0279] aspects be buffered to a selected pH. Liquid preparations are normally easier to prepare than gels, other viscous compositions, and solid compositions. Additionally, liquid compositions are somewhat more convenient to administer, especially by injection. Liquid compositions can comprise carriers, which can be a solvent or dispersing medium containing, for example, water, saline, phosphate buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol) and suitable mixtures thereof.

[0280] Sterile injectable solutions can be prepared by incorporating the cells in a solvent, such as in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, dextrose, or the like. The compositions can contain auxiliary substances such as wetting, dispersing, or emulsifying agents (e.g., methylcellulose), pH buffering agents, viscosity enhancing or viscosity reducing additives, preservatives, flavoring agents, and / or colors, depending upon the route of administration and the preparation desired. Standard texts may in some aspects be consulted to prepare suitable preparations.

[0281] Various additives which enhance the stability and sterility of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, and sorbic acid.

[0282] Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0283] The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g, by fdtration through sterile filtration membranes.

[0284] The contents of the articles, patents, and patent applications, and all other documents and electronically available information mentioned or cited herein, are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicants reserve the right to physically incorporate into this application any and all materials and information from any such articles, patents, patent applications, or other physical and electronic documents.

[0285] While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made, and equivalents may be substituted without departing from the true spirit and scope of the invention. It will be readily apparent to those skilled in the art that other suitable modifications and adaptations of the methods described herein may be made using suitable equivalents without departing from the scope of the embodiments disclosed herein. In

[0286] 33

[0287] 578332772

[0288] Attorney Docket No. 047162-7558 WO 1 (02937)

[0289] addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit, and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. Having now described certain embodiments in detail, the same will be more clearly understood by reference to the following examples, which are included for purposes of illustration only and are not intended to be limiting.

[0290] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents were considered to be within the scope of this invention and covered by the claims appended hereto. For example, it should be understood that modifications in reaction conditions, including but not limited to reaction times, reaction size / volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing / oxidizing agents, with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application.

[0291] It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges are meant to be encompassed within the scope of the present invention. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.

[0292] The following examples further illustrate aspects of the present invention. However, they are in no way a limitation of the teachings or disclosure of the present invention as set forth herein.

[0293] EXAMPLES

[0294] Example 1: Introduction.

[0295] Pulmonary inflammation induces injury to alveolar cells, contributing to acute lung injury. However, how inflammation damages alveolar cells and how lung cells coordinate responses to injury remain unclear. Here, it is shown that the aldo-keto reductase AKR1B8, produced by Foxj1+ciliated cells, protects alveolar cells from inflammation-induced ferroptotic death and injury, as demonstrated through the investigation of ciliated cell-specific knockout of the Wnt receptor FZD6. The FZD6 knockout increases Akrlb8 expression, reducing lipid peroxidation, alveolar cell death, and lung injury in response to lipopolysaccharide (LPS) or a coronavirus infection, effects that are not further altered by

[0296] 34

[0297] 578332772

[0298] Attorney Docket No. 047162-7558 WO 1 (02937)

[0299] ferroptosis inhibitors. Intratracheal administration of extracellular vesicles containing AKR1B8 protects alveolar cells from ferroptosis and mitigates lung injury, while AKR1B8 knockout exacerbates these phenotypes. These findings reveal a previously unrecognized non-cell-autonomous mechanism for ferroptosis regulation, mediated by this reductase and protecting alveolar cells during inflammation.

[0300] Acute Lung Injury (ALI) and its severe form, Acute Respiratory Distress Syndrome (ARDS), represent a serious health problem with high mortality rates. ALI / ARDS is commonly caused by bacterial and viral lung infections and is characterized by diffuse alveolar damage, neutrophilic inflammation, and increased permeabi lily of the alveolar-capillary barrier, leading to protein-rich edema and subsequent impairment of arterial oxygenation. The recent COVID-19 as well as previous Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS) are all associated with respiratory illness due to alveolar damage, which can lead to severe ALI / ARDS and progressive respiratory failure, and contribute to high mortality rates of these diseases.

[0301] Currently, there are no pharmacological interventions for ALI / ARDS. Specifically, incomplete understanding of ALI / ARDS pathogenesis and pulmonary cell responses to inflammation hampers progress in therapeutic development. Current studies have been heavily focused on the roles of immune cells and their interactions with lung cells in pulmonary tissue damage. Emerging insights highlight the important roles of airway epithelial cells, including ciliated, club, goblet, and basal cells, and the interplay between non-immune cells in protecting against acute injury.

[0302] Ferroptosis is a form of cell death caused by iron-dependent lipid peroxidation.

[0303] Mechanistically, oxygen and iron, essential drivers of metabolism, lead to the production of reactive oxygen species (ROS) and the subsequent formation of lipid peroxides. If these lipid peroxides are not efficiently neutralized and accumulate, they disrupt cellular membrane integrity, resulting in cell death. Ferroptosis plays significant roles in various diseases, including cancer, neurodegeneration, and ischemic organ injury. Ferroptosis is also implicated in lung diseases, as evidenced by the detection of lipid peroxidation and the effects of ferroptotic inhibitors. While cell intrinsic ferroptosis regulatory mechanisms have been well documented, much less is known about the non-cell autonomous mechanisms for ferroptosis regulation.

[0304] Wnt signaling regulates a wide range of physiological and pathophysiological processes. The best characterized Wnt signaling pathway is the Wnt-P-catenin pathway, in which Wnt proteins bind to their cell surface receptor Frizzled (FZD) and LDL-related

[0305] 35

[0306] 578332772

[0307] Attorney Docket No. 047162-7558 WO 1 (02937)

[0308] protein 5 / 6 (LRP5 / 6), leading to 0-catenin stabilization and -catenin-mediated transcription. There are 10 Fzd genes in mammals. Although many of them have been shown to play roles in various developmental processes, their roles in physiological and pathophysiological processes remain understudied. In this study, it was found that the loss of FZD6 in ciliated cells enhanced pulmonary barrier function and protected ferroptotic death of alveolar cells during lung inflammation induced by LPS or mouse hepatitis virus (MHV), a mouse coronavirus that produces pulmonary pathological features of SARS. Further investigation led to the finding that FZD6-deficiency increases the production of AKR1B8 in pulmonary Foxj1+ciliated cells. While the administration of the AKR1B8 protein, (for example, in the extracellular vesicle (EV)-associated form), ameliorated lung injury, loss of Akrlb8 exacerbated it. Thus, the present study led to the identification of AKR1B8 as being an important non-cell autonomous ferroptosis suppressor and unravel a previously unknown function of ciliated cells in acute lung inflammation.

[0309] Example 2: Global Fzd6 KO reduces LPS-induced lung injury.

[0310] In the investigation of a global inducible Fzd6 KO mouse line driven by Mxl-Cre, it was serendipitously found that global inducible Fzd6 KO enhanced pulmonary barrier integrity by reducing lung permeability in an LPS-induced acute lung injury model (FIG. 1A). The lung permeability was assessed by determining the contents of proteins and FITC-BSA administrated intravenously right before sample collection in the bronchoalveolar lavage (BAL). Morphometric analysis of lung histological sections showed reduced lung injury score in the global Fzd6 KO lungs compared to the Wt controls (FIGs. IB, 8A).

[0311] Collectively, these results suggest less alveolar damage in the global Fzd6 KO lungs than that in the control mice in this LPS-induced lung injury model. On the other hand, there were no obvious differences in the BAL concentrations of IL-6, TNFa, and IL- 1 p between global Fzd6 KO and Wt (FIG. 1C). Both monocytes and neutrophils showed no significant, even though trends of. reduction in the BAL and lungs of the global Fzd6 KO mice over Wt ones (FIGs. ID, 8B, 8C) Thus, the Fzd6 KO reduces lung injury without strong effects on acute inflammatory responses.

[0312] Example 3: Foxj1+cell-specific Fzd6 KO reduces lung injury.

[0313] Single-cell RNA sequencing of CD45+and CD45’ cells sorted from LPS-injured lungs was carried out. The result of this analysis found that Fzd6 was primarily expressed in CD45‘ cells, but not in CD45+cells (FIGs. 2A-2B). Additionally, the single-cell RNA sequencing analysis showed that the Foxj1+cells, which are ciliated cells, expressed Fzd6 at a

[0314] 36

[0315] 578332772

[0316] Attorney Docket No. 047162-7558 WO 1 (02937)

[0317] much higher level than other CD45" cells (FIG. 2C). The Fzd6 protein was previously detected by immunostaining at Foxj1+ciliated airway epithelial cells. Concordantly, this observation was confirmed by detecting colocalization of FZD6 on the same cells with tdTomato whose expression was driven by Foxj1-Cre (FIG. 9A). Analysis of the expression of all of the ten frizzled genes in the Foxj1+cells using this single cell RNA sequencing dataset indicated that Fzd6 appeared to be the dominate Fzd genes expressed in these Foxj1+cells (FIG. 9B).

[0318] The dominant expression of the Fzd6 gene in the ciliated cells prompted an attempt determine if the lack of FZD6 in these Foxj1+ciliated cells could recapitulate LPS-induced lung injury phenotypes of the global Fzd6 KO. Thus, FoxjF cell-specific (driven by Foxjl-Cre) Fzd6 KO mouse line, designated as Fzd6Foxj1CKO were generated. In addition, an endothelial cell-specific (driven by Cdh5-Cre) Fzd6 KO line was generated as Fzd6 expression was also detectable in some of Cdh5+endothelial cells (FIG. 2A). The mice lacking Fzd6 in the Foxj1+cells (FIG. 2D), but not those lacking Fzd6 in the endothelial cells (FIG. 9C), showed reduced lung permeability induced by LPS. In addition, Fzd6FoxjICKO also had reduced alveolar damage over the Wt control after LPS treatment (FIG.2E).

[0319]

[0320] To understand how FzdF'F1CKO regulates LPS-induced lung phenotypes, single-cell RNA sequencing of CD45-negative cells sorted from Fzd6Foxj1CKO and Wt lungs was performed. Total 9821 Wt cells and 9603 Fzd6Fox]ICKO cells passed quality control and were used in the subsequent analysis. Unsupervised clustering yielded 5 major clusters (FIGs. 3A, 9D). Based on the marker genes expression, epithelial cells are in clusters 1-3, whereas endothelial cells (EC) are in cluster 4, and fibroblast cells are in cluster 5 (FIG. 3B).

[0321] Additionally, Foxj1-positive ciliated cells are in cluster 1, whereas Type 2 and 1 alveolar epithelial cells are in clusters 2 and 3, respectively (FIG. 3B). The cell number distributions of these clusters within each genotype are shown in FIG. 3C. Differential gene expression analysis, followed by Ingenuity Pathway Analysis (IP A), revealed the enrichment of many pathways in these clusters. Among these enriched pathways, it was noticed that the ferroptosis pathway was downregulated in the C2+C3 alveolar epithelial cells (FIG.3E) and altered in the C4 endothelial cells (the direction of alteration could be not resolved) of Fzd6Foxj1CKO (FIG. 3F). In addition, the NRF2-mediated oxidative stress pathway, which is related to ferroptosis, was also altered in all clusters (FIGs.3D-3G). These data suggest a possibility that Fzd6Fox]1CKO may affect ferroptosis.

[0322] 37

[0323] 578332772

[0324] Attorney Docket No. 047162-7558 WO 1 (02937)

[0325] Example 5: Fzd6Foxj1CKO suppresses LPS-induced ferroptosis in the lung.

[0326] To determine whether Fzd6FoxjICKO affects ferroptosis in the LPS-treated lungs, it was found that the ferroptosis marker 4-hydroxynonenal (4-HNE) was detected in lung sections and that Fzd6Foxj1CKO suppressed the LPS-induced increase in 4-HNE staining (FIGs. 4A, 10A). It was also found that Fzd6Foxj1CKO reduced the BAL content of malonaldehyde (MDA, a byproduct and marker of lipid peroxidation) (FIG. 4B). These results provide evidence supporting that Fzd6Foxj1CKO suppresses ferroptosis in LPS-injured lungs.

[0327] Next, to see whether these ferroptosis marker changes correlate with changes in cell death, the lungs were perfused with propidium iodide (PI) immediately before fixation at different durations of LPS treatment. Pl-positive cells were observed in LPS-treated lung sections, whose number appeared to peak at 9 hours post LPS treatment (FIG. 10B).

[0328] Interestingly, the Pl-positive signals were largely surrounded by or in the vicinity of 4-HNE staining (FIG.4C), and the number of Pl-positive cells at this peak cell death timepoint was strongly reduced by a ferroptosis inhibitor ferrostatin-1 (FIGs. 4D, 10C). which also effectively reduced BAL MDA contents (FIG. 10D). Further analysis of these Pl-positive cells revealed that some of the PI signals were surrounded by CD31 (an endothelial cell marker) staining, whereas others by CD326 (Epcam, an epithelial cell marker) staining (FIG.

[0329] 10G), suggesting death occurs to both alveolar endothelial and epithelial cells. A few PI-positive cells were also colocalized with CD45 staining (FIG. 10H). At this timepoint, some of cells were positive for activated caspase 3, an apoptosis marker. However, most of these activated caspase 3-positive cells were Pl-negative (FIG. 10E), suggesting most of apoptotic cells have intact plasma membrane at this time. In addition, there were about twice the number of Pl-positive cells than activated caspase3-positive cells (FIG. 10F). Together with the observation that ferrostatin-1 decreases lung permeability and lung injury score (FIGs. 2D-2E), it is reasonable to believe that ferroptotic cell death is an important cell death mechanism that contributes to lung injury during LPS-induced inflammation.

[0330] Fzd6Foxj1CKO also markedly reduced the number of Pl-positive cells (FIGs.4D, 10C) without significantly affecting the number of activated caspase3 -positive cells (FIGs.

[0331] 10E-10F). In addition, those reduced PI signals in Fzd6Foxj1CKO lungs could be observed in the endothelial cells, PDPN positive ATI cells and ABCA3 positive AT2 cells (FIGs.4E-4G). Furthermore, 4-HNE staining was also markedly decreased in both lung endothelial and epithelial cells (FIGs. 4H-4J). Since ferrostatin-1 did not alter Fzd6Foxj1CKO lung injury phenotypes (FIGs. 2D-2E), it is also reasonable to conclude that ferroptosis also likely

[0332] 38

[0333] 578332772

[0334] Attorney Docket No. 047162-7558 WO 1 (02937)

[0335] underlies the lung phenotypes of Fzd6Foxj1CKO.

[0336] Example 6: Coronavirus lung infection induces ferroptotic alveolar cell death.

[0337] Next, mouse hepatitis virus (MHV), a coronavirus known to induce acute lung injury phenotypes was evaluated to determine whether it could induce ferroptotic cell death.

[0338] Intranasal MHV-A59 administration also induced marked cell death as detected by PI staining (FIG.5A). Importantly, ferroptosis inhibitors ferrostatin-1 and liproxstatin-1 markedly reduced the number of Pl-positive cells in the lung, particularly in the alveoli (FIGs. 5A-5B). In addition, these ferroptotic inhibitors also inhibited pulmonary permeability and reduced lung injury score (FIGs. 5C-5D). Liproxstatin-1 was used here because of its reported superior pharmacological kinetic properties to ferrostatin-1, and indeed, it appeared to perform better than ferrostatin-1. Fzd6Foxj1CKO, acting like the ferroptosis inhibitors, also reduced the number of Pl-positive alveolar cells and the contents of lipid peroxidation marker MDA (FIGs. 5E-5F). Concordantly, Fzd6Foxj1CKO also ameliorated MHV-induced lung injury phenotypes (FIGs. 5G-5H). Neither ferroptosis inhibitors nor Fzd6Foxj1CKO caused strong changes in BAL neutrophil presence (FIGs. 11A-11B). These results together suggest that mouse coronavirus MHV infection causes ferroptotic alveolar death, which contributes significantly to viral infection-related lung injury phenotypes. Consistent with a recent report, lipid peroxidation marker 4-HNE staining was detected in human COVID-19 lung sections, whose intensity is correlated with that of COVID-19 spike protein staining (FIG. 11C).

[0339] Example 7: Fzd6Foxj1CKO increases Akr1b8 expression.

[0340] Fzd6 inactivation in the Fzd6Foxj1CKO mice occurs within the ciliated Foxj1+cells, which line the walls of trachea, bronchioles, and brachiola. However, reduced cell death and lung injury phenotypes related to the alveolar cells in the Fzd6Foxj1CKO mice was observed. Therefore, it was suspected that the effect of Fzd6Foxj1CKO was non-cell autonomous. Upon analysis of the differentially expressed genes (DEGs) between Fzd6Foxj1CKO and Wt in the Foxj1+cells using the single cell RNA sequencing dataset, Akr1b8, w hich is preferentially expressed in Foxj1+ ciliated cells over other CD45" lung cells (FIG. 6A) and absent in CD45+lung cells (FIG. 2B), was found to be significantly upregulated by Fzd6Foxj1CKO (FIGs. 6A-6B). The Akrlb8 gene encodes the aldo-keto reductase family 1 member B8 protein.

[0341] Consistent with gene expression, the AKR1B8 protein was primarily detected in pulmonary tubular epithelial cells and upregulated in the Fzd6Foxj1CKO mice upon LPS treatment, which also upregulated AKR1B8 protein (FIG. 6C). Of note, Fzd6Foxj1CKO itself did not show a strong effect on ARK1B protein expression in the absence of LPS treatment. AKR proteins

[0342] 39

[0343] 578332772

[0344] Attorney Docket No. 047162-7558 WO 1 (02937)

[0345] including AKR1B8 have broad ranges of substrates including aldehydes and their glutathione conjugates and were suggested to suppress ferroptosis by reducing lipid peroxidation products. Moreover, AKR1B8 and some of the human AKR1 molecules were detected in the conditioned media, suggesting these reductases may be able to act non-cell autonomously. Therefore, it was hypothesized that AKR1B8 produced from ciliated cells may suppress ferroptosis of alveolar cells in a cell non-autonomous manner, which is consistent with the enrichment of the xenobiotic metabolism pathway in lung cells revealed by the single-cell RNA sequencing analysis (FIGs. 3D, 3G). The impact on the xenobiotic metabolism pathway is possibly due to AKRlB8’s broad reductase substrate specificity. In supporting the hypothesis of non-cell autonomous action of AKR1B8, an increased amount of the protein in the BALs from the Fzd6 KO lungs was detected compared to that in the Wt BALs post LPS treatment (FIG. 6D).

[0346] Example 8: Extracellular vesicle-associated AKR1B8 regulates lung cell death and injury.

[0347] To investigate whether AKR1B8 protein affects LPS-induced lung injury, conditioned medium (CM) from HEK293 cells expressing AKR1B8 was generated. Western blot analysis confirmed the presence of AKR1B8 protein in the CM (FIG. 12A). Next, the ability of AKR1B8 CM to suppress ferroptosis induced by the chemical ferroptosis inducer RSL3 in cultured cells was examined. AKR1B8 CM significantly inhibited RSL3-induced cell death, whereas control CM had no effect (FIG. 6E, blue dots).

[0348] In vivo, intratracheal instillation of AKR1B8 CM into mice subjected to LPS-induced lung inflammation substantially reduced the number of Pl-positive cells in the lungs (FIG.

[0349] 6F), decreased malondialdehyde (MDA) levels in the bronchoalveolar lavage (BAL) fluid (FIG. 6G), and mitigated pulmonary permeability and injury scores (FIGs. 6H-6I). These effects occurred without significantly altering BAL neutrophil infiltration (FIG. 12B).

[0350] Given that AKR1B8 lacks a conventional signal peptide or cell-penetrating sequence, it was hypothesized that it might be released and delivered via extracellular vesicles (TVs), which are known to facilitate intercellular communication. To test this, EVs and EV-depleted CM from the conditioned medium were isolated using centrifugal concentration and precipitation methods (FIG. 12C). EVs derived from AKR1B8-expressing cells, but not those from GFP-expressing control cells, suppressed RSL3-induced ferroptotic cell death in a dose-dependent manner (FIG.6E, red dots). However, EV-depleted CM, despite containing equal or higher amounts of AKR1B8 protein as shown by Western blotting (FIG. 12D),

[0351] 40

[0352] 578332772

[0353] Attorney Docket No. 047162-7558 WO 1 (02937)

[0354] failed to inhibit ferroptosis (FIG. 6E, green dots). Furthermore, only EVs containing AKR1B8, and not those from GFP-expressing cells or EV-depleted CM, reduced lung permeability induced by LPS (FIG. 12E).

[0355] The EVs prepared as described in FIG. 12A underwent further characterization. Nanoparticle tracking analysis revealed that EVs derived from the CM of AKR1B8-expressing 293T cells exhibited similar particle number and size distribution compared to those from GFP-expressing 293T cells (FIG. 12H), indicating that AKR1B8 expression does not significantly alter EV production or physical characteristics. To investigate the surface markers of AKRlB8-containing EVs, immunoprecipitation of EVs was performed using a mixture of antibodies against CD9, CD63, and CD81. Western blot analysis confirmed the presence of AKR1B8 in the immunoprecipitated EVs (FIG. 121). suggesting that AKR1B8-containing EVs carry classical EV marker proteins. All of these results together demonstrate that AKR1B8 exerts its cell non- autonomous anti-ferroptotic effects through conventional EVs.

[0356] The exact human ortholog of mouse AKR1B8 remains a subject of debate. Therefore, EVs were prepared from the CMs of HEK293 cells expressing three different human AKR1 proteins: AKR1B1, AKR1B10, and AKR1C3. EVs containing any of these human AKR1 proteins demonstrated significant suppression of ferroptosis (FIGS. 6J and 12J).

[0357] Additionally, recombinant AKR1B10 protein purified from the baculovirus expression system, exhibited ferroptosis protective effects only when encapsulated in liposomes. In contrast, the free form of the protein or the protein simply mixed with pre-formed liposomes showed no such protective effect (FIG. 6K). These findings demonstrate that human AKR1 proteins, like mouse AKR1B8, suppress ferroptosis in a cell non-autonomous manner via EVs. Furthermore, they confirm that the AKR1 protein itself, rather than indirect effects on EVs or their contents, is responsible for ferroptosis suppression.

[0358] Example 9: EV-mediated delivery of AKR1B8 acts as a non-cell-autonomous mechanism to suppress ferroptotic lipid peroxidation and protect against LPS-induced lung injury.

[0359] Extracellular vesicles (EVs) isolated from the bronchoalveolar lavage (BAL) fluid of inflamed lungs were evaluated to see whether they could suppress LPS-induced injury. BAL fluid was collected from LPS-treated Akrlb8- / - mice and ciliated cell-specific Fzd6 knockout (KO) mice — representing the two extremes of AKR1B8 expression — and EVs were subsequently isolated. When delivered intratracheally with LPS, EVs from Fzd6 KO mice

[0360] 41

[0361] 578332772

[0362] Attorney Docket No. 047162-7558 WO 1 (02937)

[0363] markedly reduced lung permeability. In contrast, EVs derived from Akrlb8- / - mice offered no protective effects (FIG. 13A). Next, to examiner whether AKR1B8 protein is transferred from Foxjl+ ciliated cells to alveolar cells during lung inflammation, populations enriched for ciliated, endothelial, and alveolar epithelial (Type I and Type II) cells were sorted from the LPS-treated lungs of Wt, Fzd6si, and Akrlb8- / - mice. Western blot analysis confirmed a robust upregulation of AKR1B8 in ciliated cells upon Fzd6 deletion (FIG. 13B). Notably, marked increases in AKR1B8 protein were detected within endothelial and epithelial cells from Fzd6 KO mice compared to Wt controls (FIGs. 13C-13E). The magnitude of these protein increases was comparable to those observed in ciliated cells (FIG. 13B) and in BAL-isolated EVs (FIG. 13F). While low baseline detectability of AKR1B8 in Wt samples limited precise quantification in endothelial and Type II cells, the substantial protein-level increases contrast sharply with the minimal changes in Akrlb8 mRNA across these same populations (FIG. 6A). Together, these findings indicate that the elevated AKR1B8 protein in endothelial and epithelial cells does not arise from local transcription, but rather reflects intercellular transfer — likely from ciliated cells via EVs. To further substantiate the anti-ferroptotic function of AKR1B8 during lung inflammation, mass spectrometry-based hpidomic analysis on lung tissues was performed. Mice were treated with LPS in combination with control EVs, control EVs plus the ferroptosis inhibitor Liproxstatin-1, or AKRlB8-enriched EVs. LPS treatment significantly upregulated fourteen oxygenated phosphatidylethanolamine (PE) species (FIGs. 13G-13H). including arachidonic acid-containing PE plasmalogens (PEp-40:4+2(O)-H and PEp-40:5+2(O)-H) and linoleic acid-containing PE (PE-32:2+3(O)-H) (FIG. 13H). The oxygenation of these specific fatty' acids is a recognized hallmark of ferroptosis, particularly given the critical role of plasmalogens in this cell death pathway. Notably, the induction of all oxygenated PE species by LPS was markedly attenuated by AKRlB8-containmg EVs, achieving a degree of suppression comparable to Liproxstatin-1 treatment (FIGs. 13G-13H). These results are further supported by observations in vitro, where AKRlB8-containing EVs protected both LLC lung cancer cells and MLE-12 immortalized lung epithelial cells from RSL3-induced ferroptosis (FIGs. 13I-13J).

[0364] Collectively, these findings establish that the EV-mediated delivery of AKR1B8 serves as a potent non-cell-autonomous mechanism that inhibits lipid peroxidation and maintains pulmonary' integrity7during inflammatory7injury.

[0365]

[0366] To further corroborate the importance of AKR1B8 in ferroptosis protection, the effect

[0367] 42

[0368] 578332772

[0369] Attorney Docket No. 047162-7558 WO 1 (02937)

[0370] of AKRlB8-deficiency in Akrlb8 KO mice was examined on LPS-induced alveolar cell death and lung injury’ phenotypes (FIG. 14A). Opposite to the phenotypes of AKR1B8 protein administration, Akrlb8 KO increased the number of Pl-positive and 4-HNE positive alveolar cells compared to Wt, accompanied with increases in pulmonary permeability’ and lung injury score (FIGs. 7A-7F). Together with upregulation of AKR1B8 protein by LPS (FIG. 6C), these results support an important role of AKR1B8 in the protection of inflammation-induced ferroptotic lung cell death and acute lung injury. Additionally, Akrlb8 KO mice were crossed with the Fzd6Fox j1CKO mice to produce the double knockout (DKO) mice. The DKO did not further alter these phenotypes compared to those of the Akrlb8 KO. Again, neither Akrl b8 KO nor DKO strongly affected the BAL neutrophil infiltration (FIG.

[0371] 14B). Given the preferential expression of Akrlb8 in ciliated cells, it is reasonable to conclude that the effects of Foxjl -specific Fzd6 KO on LPS-induced lung inflammation are largely attributed to Fzd6 regulation of AKR1B8 production from the Foxj1+ ciliated lung cells and non-cell autonomous action of AKR1B8 on alveolar cells (FIG. 15).

[0372] Example 11:

[0373] This study demonstrated that the deficiency of the Wnt receptor Fzd6 in Foxj1+ciliated cells resulted in suppressed pulmonary permeability, lipid peroxidation, and alveolar cell death during lung inflammation induced by LPS or coronavirus infection. Additionally, evidence that Fzd6 deficiency suppresses LPS-induced ferroptosis by upregulating and releasing the aldo-keto reductase AKR1B8 from Foxj1+ ciliated cells in the lung was presented. These findings uncover an unexpected role for ciliated cells and the aldo-keto reductase AKR1B8 in protecting alveolar cells from ferroptotic cell death during lung inflammation. Additionally, it was shown that the anti-ferroptotic action of AKR1B8, likely shared by other AKR1 family members, relies on EVs, revealing a previously unrecognized role for EVs in a non-cell -autonomous mechanism of ferroptosis regulation.

[0374] While emerging evidence has highlighted the roles of the interplay between non-hematopoietic lung cells in acute injury protection, ciliated cells are not known to protect alveolar cells from acute injury’ during lung inflammation. Ciliated cells line the walls of the trachea, bronchi, and bronchioles, with their primary function being to clear microorganisms, mucus, and other debris from the respiratory’ system through the rhythmic beating of their cilia. They have not been shown to signal to or impact alveolar cells. In this study, several lines of evidence were presented to support the conclusion that Foxj1+ ciliated cells produce AKR1B8 to protect alveolar cells from ferroptotic death and injury during lung inflammation:

[0375] 43

[0376] 578332772

[0377] Attorney Docket No. 047162-7558 WO 1 (02937)

[0378] 1) Foxj1-specific Fzd6 KO reduces alveolar ferroptotic death and lung injury phenoty pes. 2) Inactivation of Akrlb8, whose expression is preferentially in the Foxj1+cells and upregulated by LPS-induced inflammation, increases alveolar cell death and exacerbates lung injury phenotypes. 3) Fzd6Foxj1and Akrlb8 DKO shows lung injury phenotypes similar to those of Akrlb8 single KO, suggesting FZD6 functions through AKR1B8, whose expression is up-regulated by Fzd6 KO in ciliated cells.

[0379] In this study, evidence was further presented showing that AKR1B8 produced by ciliated cells is delivered to alveolar cells via extracellular vesicles (EVs). The evidence includes that only EV-associated AKR1B8, but not the free form in the conditioned medium, suppressed ferroptosis in a cell-based assay and protected lungs from injury. This point was further confirmed by the observation that purified recombinant AKR1 protein, only when encapsulated in liposomes, could suppress ferroptosis. This requirement of EVs was interpreted as being due to the localization of polyunsaturated fatty acids (PUFAs), which are prone to lipid peroxidation, primarily within the inner leaflets of plasma membranes. In addition, lipid peroxidation also occurs in the membranes of intracellular organelles.

[0380] Therefore, AKR1B8 is needed to be delivered to the inside of target cells, in this case by EVs, to effectively suppress lipid peroxidation and ferroptosis. While AKR proteins are known to regulate ferroptosis through their enzymatic activity toward lipid peroxidation derivatives such as 4-HNE and MDA, the evidence presented herein demonstrates the critical role of AKR-mediated ferroptosis inhibition in an in vivo context.

[0381] Example 12: Materials and Methods.

[0382] Mice.

[0383]

[0384] mice were obtained from The Jackson Laboratory. Akrlb8+ / - mice (C57BL / 6N-4U' / 5< S’'"'A',', <2’' / A''rfc;’7JMmucd) were obtained from MMRRC. Mx1Creand Cdh5CreER2were described previously. All mice used in this study were back-crossed with the C57BL / 6N background. Fzd6 gene disruption was induced by intraperitoneal injection of 40 ul of poly-I: C (10 mg / ml) into the Mx1Cremice every' other day for four treatments or by intraperitoneal injection of 100 ul tamoxifen (10 mg / ml) for 6 consecutive days into the FoxJ1CreER2and Cdh5CreER2mice. All animal experiments were performed with the approval of the Institutional Animal Care and Use Committee at Yale University.

[0385] LPS-induced lung inflammation.

[0386] Mice were anesthetized with ketamine / xylazine (100 and 10 mg / kg). A 22-gauge

[0387] 44

[0388] 578332772

[0389] Attorney Docket No. 047162-7558 WO 1 (02937)

[0390] catheter (Jelco, Smiths Medical) was guided 1.5 cm below the vocal cords, and LPS (50 µl, 1 mg / ml, Escherichia coli Oil: B4) was instilled while mice postures were maintained upright. Sixteen hours after the induction of injury, 100 µl of fluorescein isothiocyanate-labeled albumin (FITC-BSA, 10 mg / ml) was injected into mice via retro-orbital vein. Mice were then euthanized for sample collection 1-2 hours later. BALs were collected after 1 ml of PBS was instilled into lungs and retrieved via a tracheal catheter. For the baseline permeability measurement, saline without LPS was administered the same way. The baseline permeability measurement was subtracted in the data presented.

[0391] For ferrostatin-1 (Fs-1) treatment, mice were administrated with Fs-1 (1.0 mg / kg) via retro-orbital vein one hour after LPS instillation. Fs-1 was dissolved in DMSO at the concentration of 200 mg / ml and diluted to a concentration of 0.2 mg / ml in PBS.

[0392] Histology and histomorphology.

[0393] The right ventricles were perfused with 10 ml of PBS, and the lungs were inflated with 4% paraformaldehyde at a constant pressure of 25 cm H2O. The lungs were then fixed in 4% paraformaldehyde for 24 h at 4 °C. The lung tissues were embedded in paraffin. They were cut into 5 pm-thick sections and stained with H& E at the Comparative Pathology Research Core at Yale School of Medicine. The sections were imaged using the Keyence BZ-X800 microscope. Lung injury’ score was quantified as described. All measurements were done by two blinded observers.

[0394] Flow cytometry analysis of BAL and lung-infiltrating leukocytes.

[0395] Leukocytes in BAL were pelleted by centrifugation (500 x g for 5 min at 4 °C), followed by staining and flow cytometry. To prepare lung-infiltrating leukocytes, mouse right ventricles were perfused with 10 ml of PBS, excised, gently disrupted by teasing, and resuspended in RPMI-1640 medium supplemented with 250 U / ml of collagenase, 400 U / ml elastase and 50 U / ml of DNAse. Lungs were then enzymatically digested for 40 min at 37 °C. Dispersed cells were filtered through a 70-µm cell strainer to eliminate clumps and debris. After centrifugation for 5 min (500 x g) at 4 °C, cell pellets were resuspended in RBC lysis buffer (Sigma-Aldrich, R7757) and incubated at room temperature for 5 min to remove erythrocytes. Cells were pelleted again and resuspended in PBS, fixed with 2% PFA (Santa Cruz, sc-281692), and stained with antibodies for 1 h on ice in the dark.

[0396] Antibodies used for flow cytometry are as follows: mouse CD45-BUV395 (BD Biosciences), mouse Ly6G-Pacific Blue (BioLegend), and mouse Ly6C-FITC (BioLegend).

[0397] Lung endothelial cell and epithelial cell isolation.

[0398] Lungs were digested as previously described. Briefly, the lung single-cell suspensions

[0399] 45

[0400] 578332772

[0401] Attorney Docket No. 047162-7558 WO 1 (02937)

[0402] were prepared by perfusing the right ventricle with PBS to remove blood. The lungs were then inflated in situ with a digestion cocktail containing elastase (Worthington Biochemical LS002292), dispase (Sigma-Aldrich D4693), and DNase (Sigma-Aldrich 11284932001), followed by incubation at 37 °C for 45 minutes. After removal of the trachea, lung tissue was mechanically minced and gently agitated in cold RPMI, then passed through a 70 µm cell strainer. To maximize yield, the remaining tissue was subjected to a second round of enzymatic digestion for 30 minutes at 37 °C. The resulting cell suspensions were pooled, neutralized with FACS buffer, and centrifuged at 500 x g. Residual red blood cells were removed using ACK lysis and single-cell suspension were sorted for endothelial and epithelial cells by BD Facs Aria.

[0403] BAL Cytokine measurement (ELISA).

[0404] BALs were centrifuged at 800xg at 4 °C for 10 min to collect cell-free BAL supernatants. The levels of IL-6, IL-1β and TNF-α were determined by using enzyme-linked immunosorbent assay (ELISA) kits specific for the cytokines according to the manufacturer's instructions (Proteintech).

[0405] BAL MDA measurement.

[0406] BAL MDA contents were determined using the MDA adduct competitive ELISA kit (Cell Biolabs, Cat#: STA-832) according to the manufacturer’s instructions.

[0407] In vivo propidium iodide (PI) staining.

[0408] Mice were perfused transcardially with PI (Sigma-Aldrich, P4170, 0.75 mg / ml.

[0409] 4 ml / mice in PBS) for 10 min. The lungs were then fixed by perfusing transcardially with 4 ml 4% PFA (containing 0.5 mg / ml PI) 10 min. Lung architecture was preserved by inflation the lung with OCT solution (OCT: PBS = 1: 1), followed by additional fixation with 4% PFA for overnight. The lungs were then transferred to 30% sucrose and incubated for additional 24 hrs. Finally, the lung samples were embedded in OCT and stored at -80 °C until sectioning. Sections (10 µm) were counterstained with DAPI and examined under a fluorescent microscope.

[0410] Akrlb8 conditional medium preparation.

[0411] The cDNA for mouse AKRlb8 was obtained from Horizon (Cat# MMM1013-202763109) and subcloned to a mammalian expression vector. HEK-293T cells were maintained in DMEM supplemented with 10% FBS at 37 °C and transfected with Akrlb8 expression plasmid or empty vector using Lipofectamine LTX. After overnight, the cells were washed three times with PBS and then replaced with 100 mL of fresh DMEM media without FBS. After 24 h, the conditioned media (CMs) were collected and centrifuged at

[0412] 46

[0413] 578332772

[0414] Attorney Docket No. 047162-7558 WO 1 (02937)

[0415] 15000×g for 5 min at room temperature. The CMs were concentrated with a 10K Amicon Ultra-15 centrifuge tubes (Merck Millipore Ltd., Saint-Quentin-Fallavier, France) by 10-fold. The CMs were then diluted 30 folds into PBS, and 50 pL were used for intratracheal instillation.

[0416] For EV and EV-depleted CM preparation, the CMs were separated into concentrate and flow-through fractions using a 100K Amicon Ultra-15 Centrifugal Filter Unit (Cat: UFC910024). The concentrates were subjected to EV isolation using the Total Exosome Isolation Reagent (Cat: 4478359, Invitrogen) as per the manufacturer's instructions, whereas the flow-through fractions were subjected to another round of concentration using a 10K Amicon® Ultra-15 Centrifugal Filter Unit (Cat: UFC901024). The concentrated flow-through, which is depleted of EV and hence considered as EV-depleted CM. and isolated EVs were adjusted to the same equivalent volume to concentrated original CM.

[0417] For EV preparation by density gradient ultracentrifugation, the EV preparations isolated above were resuspended in ice-cold PBS and iodixanol (STEMCELL Technologies #07820) (OptiPrep) to achieve a final concentration of 36% (wt / vol) iodixanol. This suspension was placed at the bottom of a centrifugation tube. Solutions were carefully layered on top with decreasing iodixanol concentrations (30%, 24%, 18%, and 12%) in PBS and subjected to ultracentrifugation at 120,000 x g for 15 hours. Twelve individual fractions (1 ml each) were collected from the top of the gradient. The first six fractions (the EV fraction) were pooled into one tube, while the last six fractions were pooled into a second tube. Both tubes were diluted with PBS and subjected to ultracentrifugation at 120,000 x g for 4 hours. The resulting pellets represented purified EVs and non-vesicular extracellular particles (NVEPs), respectively.

[0418] For EV isolation by immunoprecipitation, EVs isolated using the Total Exosome Isolation Reagent were incubated with 50 µL MicroBeads bound with antibodies to CD9, CD63 or CD81 (Miltenyi Biotec) for 1 hour at room temperature in a MACSmix Tube Rotator in the dark. The mixture was applied to an equilibrated a µ column placed in a µMACS Separator (Miltenyi Biotec). The p column was washed, and the EV-binding beads were eluted the absence of the magnetic field.

[0419] For nanoparticle tracking analysis (NTA) of isolated EVs, the ZetaView QUATT® machine (Particle Metrix) in scatter mode with a 488 nm laser was used. Data were analyzed with ZetaView® software version 8.05.10 (Particle Metrix).

[0420] Cell-based ferroptosis assay.

[0421] The 293T HEK cells were plated in a 48-well plate at a density of 50,000 cells per

[0422] 47

[0423] 578332772

[0424] Attorney Docket No. 047162-7558 WO 1 (02937)

[0425] well for 24 hours. CM, EV or EV-depleted CM were added one hour prior to ferroptosis induction by the addition of RSL3 (Cat: S8155, Selleck Chemicals) at a concentration of 0.45 µM for 24 hours. Live cells were determined by the ATPlite Luminescence Assay System (Cat: 6016943, Perkin Elmer) according to the manufacturer's instructions.

[0426] Mass-spectrometry analysis of oxygenated lipids.

[0427] Lipids were extracted from mouse lungs using the Folch method. Briefly, lung tissues were resuspended in 0.75% KC1, followed by extraction with a chloroform-methanol mixture (2:1, v / v). To minimize lipid oxidation during extraction and LC / MS sample preparation, 0.01% butylated hydroxytoluene (BHT) was included in the solvent mixture.

[0428] Lipid and oxygenated lipid species were analyzed by LC / ESI-MS using a Thermo HPLC system coupled to an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific). Normal-phase chromatography was carried out on a silica column (Luna 3 µm Silica (2) 100 A, 150 x 1.0 mm, Phenomenex) at a flow rate of 0.065 mL / min.

[0429] LC / MS data processing was performed using Compound Discoverer™ 2.0 software (Thermo Fisher Scientific, San Jose. CA) with a custom-built workflow and an oxidized phospholipid database. Peaks with a signal-to-noise ratio greater than 3 were selected and matched against the database. Lipid species were identified based on retention time, accurate mass, and fragmentation spectra, with m / z values matched within 5 ppm. Retention times for each lipid class were established using exogenously added internal standards.

[0430] Deuterated phospholipids (Avanti Polar Lipids) served as internal standards and were added directly to MS samples at a final concentration of 1 pM. Quantification of phospholipids and oxidized phospholipid species was based on peak areas. Data are expressed as pmol normalized to nmol of total phospholipids.

[0431] MHV-A59 lung infection model.

[0432] Mice were anesthetized with ketamine / xylazine and instilled with 30 µl PBS containing MHV-A59 intranasally. For ferroptosis inhibitor treatment, mice were injected with ferrostatin-1 (1.0 mg / kg) via retro-orbital vein or Liproxstatin-1 (8 mg / kg) intraperitoneally 24 hours after viral infection.

[0433] Human CO VID-19 lung sections.

[0434] Normal and COVID-19 lung sections were acquired from Gnome Sciences and Diagnostics (Powell, OH). The normal lung sections are from a female (45 years old) with no known lung diseases. The COVID-19 lung sections are from three COVID-19 patients: F66, an 81 years old female with a low amount of COVID-19 present; F58, a 58 years old male with an intermediate amount of COVID-19 present; F50, a 59 years old female with a high

[0435] 48

[0436] 578332772

[0437] Attorney Docket No. 047162-7558 WO 1 (02937)

[0438] amount of COVID- 19 present by clinical diagnosis.

[0439] Immunohistochemistry.

[0440] For mouse lungs, they were perfused, inflated, and fixed with 4% PFA for 4-6 h on a shaker at 4 °C. They were then washed with PBS three times and perfused in 30% sucrose solution in PBS overnight at 4 °C. They were subsequently mounted in OCT embedding compound and frozen first at -20 °C and then at -80 °C. Tissue sections were prepared at 8-µm thickness with a cryostat and mounted onto gelatin-coated histological slides, which were stored at -80 °C. For immunostaining, slides were thawed to room temperature, fixed in pre-cooled acetone for 10 min, and then rehydrated in PBS for 10 min. The slides were incubated in a blocking buffer (1% horse serum and 0.02% Tween 20 in PBS) for 1 h at room temperature, then incubated with antibodies diluted in the blocking buffer overnight at 4 °C. The slides were then washed three times with PBS and incubated with a secondary Ab in the incubation buffer for 1 h at room temperature. For human lung section staining, the slides were deparaffinized, and rehydrated, followed by antigen retrieval and antibody staining. All of the slides were finally mounted with an anti-fade mounting medium containing DAPI (Thermo Fisher Scientific, P36931) and visualized with confocal microscope (Leica SP5). Fluorescence images were quantified by using ImageJ software. Antibodies used are: anti-Fzd6 (Novus, AF1526), anti-CD326 Abs (Invitrogen, MA5- 12436), anti-CD31 (BioLegend 102421), anti-4-HNE (Abcam ab46545), anti-Spike protein (GeneTex GTX632604), and anti-activated caspase 3 (ThermoFisher 560627).

[0441] For 4-HNE staining in the MLE-12 cells, cells were treated with 1 µM RSL3 + Control exosome, 1µM RSL3+AKR Exosome, 1µM RSL3+Liproxstatin-1 for 8 h in 24-well plate. Medium was removed and the cells were gently washed. The cells were fixed by 4% paraformaldehyde (PFA) and were permeabilized with 0.03% saponin. The cells were then washed with PBST. Then the cells were blocked with 5% goat serum (ThermoFisher 50197Z) in PBST for 1 h at room temperature. The cells were incubated with anti-4-hydroxynonenal antibody (Abeam Cat# ab46544, 1:200 dilution), in PBST with 1% BSA and 5% goat serum overnight at 4°C. The cells were washed with PBST for 5 min three times. The cells were incubated with Secondary Antibody at room temperature for 1 h. The cells were washed with PBST for 5 min three times and mounted with DAPI to stain the nucleus. All images were captured on a Leica Stellaris confocal microscope.

[0442] Liposome preparation.

[0443] Liposomes were prepared as previously reported with modifications. See Koide, H. et al. J Mater Chem B 10, 6768-6776 (2022); Xu, X., Costa, A. & Burgess, D. J. Pharm Res 29,

[0444] 49

[0445] 578332772

[0446] Attorney Docket No. 047162-7558 WO 1 (02937)

[0447] 1919-1931 (2012); and Zhang, Y. et al. Dev Cell 27, 215-226 (2013). DOPC (Avanti 850375), DPPS (Avanti 840037) and Cholesterol (Avanti 700000P) at a molar ratio of 10: 1: 1 were dissolved in the organic solvent (CHCl3 / MeOH / H2O). The lipids were dried with N2 and subsequently rehydrated with reconstitution buffer (25 mM HEPES pH 7.4, 100 mM KC1, 10% glycerol) with or without the recombinant AKR1B10 protein acquired from R & D (7529-DH-020). After vortexing at maximum speed for 3 minutes, the mixture was freeze-thawed six times using liquid nitrogen, followed by 10 mins sonication in a bath sonicator. Liposomes were pre-incubated with HEK293T cells for 2hrs before RSL-3 was added to induce ferroptosis. Twenty-four hours later, the number of live cells were determined.

[0448] Single-cell RNA sequencing and analysis.

[0449] Mouse right ventricles were perfused with 10 ml of PBS, excised, gently disrupted by teasing and resuspended in RPMI-1640 medium supplemented with 250 U / ml of collagenase, 400 U / ml elastase and 50 U / ml of DNases. Lungs were then enzymatically digested for 40 min at 37 °C. Dispersed cells were filtered through a 70-µm cell strainer to eliminate clumps and debris, and erythrocytes were lysed using the lysing buffer. Cells in single-cell suspension were resuspended in cold 0.1% BSA / PBS. Following live / dead staining with viability dye (Fixable Viability Dye eFluor 506, eBioscience), cells were incubated with a Fc-blocking reagent (BD Biosciences) for 5 minutes at 4 °C and then incubated with an anti-CD45.2 mAb-PE-Cy7 antibodies for 1 hour at 4 °C. Cells were sorted using a 100 pm nozzle and 40 psi pressure (FACS Aria instrument, BD Biosciences). Single-cell 3’ RNA-seq libraries were prepared using the Chromium Single-cell V3 Reagent Kit and Controller (1 Ox Genomics). Libraries were assessed for quality control and then sequenced using a HiSeq 4000 instrument (Illumina). The demultiplexing, barcoded processing, gene counting, and aggregation were performed using the Cell Ranger software v3.1.0 with reference transcriptome GRCh38. Further downstream analysis was performed in Seurat V4.3.0.

[0450] Initially, cells were chosen based on unique feature counts less than 2500 or greater than 200 and mitochondrial read counts <5% and data is log normalized. After filtering the cells, UMI counts were variance-stabilized using scTransform with 3000 most variable features. Top 30 principal components were used to construct SNN graph and embedding with UMAP. Major cell types were detected using expression of key cell type markers across clusters.

[0451] Differential gene expression analysis was performed between two conditions and fold change were measured. All raw and processed data of this study were deposited at Gene Expression Omnibus database (GSE222810).

[0452] 50

[0453] 578332772

[0454] Attorney Docket No. 047162-7558 WO 1 (02937)

[0455] ENUMERATED EMBODIMENTS

[0456] Embodiment 1. A composition comprising a liposome; and an aldo-keto reductase family 1 (AKR1) protein associated with the liposome.

[0457] Embodiment 2. The composition of Embodiment 1, wherein the AKR1 protein is encapsulated in the liposome.

[0458] Embodiment 3. The composition of any one of Embodiments 1-2. wherein the aldoketo reductase family 1 (AKR1) protein is an aldo-keto reductase family 1 member B (AKR1B) protein or an aldo-keto reductase family 1 member C (AKR1C) protein.

[0459] Embodiment 4. The composition of any one of Embodiments 1-3, wherein the AKR1 protein is a human ortholog of the mouse AKR1B8 protein.

[0460] Embodiment 5. The composition of Embodiment 4, wherein the AKR1 protein is a human protein selected from the group consisting of AKR1B1, AKR1B10, AKR1B15, and AKR1C3.

[0461] Embodiment 6. The composition of any one of Embodiments 1-5, wherein the AKR1 protein is modified.

[0462] Embodiment 7. The composition of Embodiment 6, wherein the modified AKR1 protein is PEGylated, acetylated, fused with an amino acid sequence, or a combination thereof.

[0463] Embodiment 8. The composition of Embodiment 7, wherein the amino acid sequence is configured for purification, identification, stability, or a combination thereof.

[0464] Embodiment 9. The composition of any one of Embodiments 6-8, wherein the modified AKR1 protein has at least 70% amino acid sequence homology to a wild-type human AKR1 protein selected from the group consisting of AKR1B1, AKR1B10, AKR1B15, and AKR1C3.

[0465] Embodiment 10. The composition of Embodiment 9, wherein the modified AKR1 protein has between 80% and 99% homology to the wild-type human AKR1 protein.

[0466] Embodiment 11. The composition of any one of Embodiments 1-10, further comprising a pharmaceutically acceptable carrier.

[0467] Embodiment 12. A method of treating a subject having lung inflammation, the method comprising administering to a subject in need thereof a composition of any one of Embodiments 1-11.

[0468] Embodiment 13. The method of Embodiment 12, wherein the administering comprises intranasal administration, intratracheal administration, intravenous (IV) administration, inhalation administration, or a combination thereof.

[0469] 51

[0470] 578332772

[0471] Attorney Docket No. 047162-7558 WO 1 (02937)

[0472] Embodiment 14. The method of any one of Embodiments 12-13, wherein the lung inflammation is acute lung inflammation.

[0473] Embodiment 15. The method of Embodiment 14, wherein the administering of the composition reduces pulmonary damage caused by the acute lung inflammation.

[0474] Embodiment 16. The method of Embodiment 12, wherein the lung inflammation is caused by a lung inflammation-related disease.

[0475] Embodiment 17. The method of Embodiment 16, wherein the lung inflammation related disease comprises acute respiratory distress syndrome (ARDS), a bacterial infection, bacterial infection-related pneumonia, a viral infection, an ischemia-reperfusion injury, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, cystic fibrosis, asthma, or a combination thereof.

[0476] Embodiment 18. The method of Embodiment 17, wherein the lung inflammation-related disease is acute respiratory distress syndrome (ARDS).

[0477] Embodiment 19. The method of Embodiment 18, wherein the administering of the composition reduces ferroptosis in the subject.

[0478] Embodiment 20. The method of Embodiment 19, wherein the administering of the composition reduces ferroptotic alveolar cell death in the subject.

[0479] Embodiment 21. The method of Embodiment 17, wherein the viral infection is respiratory syncytial virus (RSV) infection, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle Eastern respiratory syndrome coronavirus (MERS-CoV), other coronavirus infection, or a combination thereof.

[0480] Embodiment 22. The method of any one of Embodiments 12-21, wherein the administering of the composition reduces at least one of pulmonary permeability, lipid peroxidation, and ferroptotic alveolar cell death in the subject.

[0481] The foregoing outlines features of several embodiments so that those skilled in the art may better understand the aspects of the present disclosure. Those skilled in the art should appreciate that they may readily use the present disclosure as a basis for designing or modifying other processes and structures for carrying out the same purposes and / or achieving the same advantages of the embodiments introduced herein. Those skilled in the art should also realize that such equivalent constructions do not depart from the spirit and scope of the present disclosure, and that they may make various changes, substitutions, and alterations herein without departing from the spirit and scope of the present disclosure.

[0482] The contents of the articles, patents, and patent applications, and all other documents

[0483] 52

[0484] 578332772

[0485] Attorney Docket No. 047162-7558 WO 1 (02937)

[0486] and electronically available information mentioned or cited herein, are hereby incorporated by reference in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. Applicants reserve the right to physically incorporate into this application any and all materials and information from any such articles, patents, patent applications, or other physical and electronic documents.

[0487] In sum, while this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

[0488] 53

[0489] 578332772

Claims

Attorney Docket No. 047162-7558 WO 1 (02937)CLAIMSWhat is claimed is:

1. A composition comprising:a liposome; andan aldo-keto reductase family 1 (AKR1) protein associated with the liposome.

2. The composition of claim 1, wherein the AKR1 protein is encapsulated in the liposome.

3. The composition of any one of claims 1-2. wherein the aldo-keto reductase family 1 (AKR1) protein is an aldo-keto reductase family 1 member B (AKR1B) protein or an aldo-keto reductase family 1 member C (AKR1C) protein.

4. The composition of any one of claims 1-3. wherein the AKR1 protein is a human ortholog of the mouse AKR1B8 protein.

5. The composition of claim 4, wherein the AKR1 protein is a human protein selected from the group consisting of AKR1B1, AKR1B10, AKR1B15, and AKR1C3.

6. The composition of any one of claims 1-5. wherein the AKR1 protein is modified.

7. The composition of claim 6, wherein the modified AKR1 protein is PEGylated, acetylated, fused with an amino acid sequence, or a combination thereof.

8. The composition of claim 7, wherein the amino acid sequence is configured for purification, identification, stability, or a combination thereof.

9. The composition of any one of claims 6-8. wherein the modified AKR1 protein has at least 70% amino acid sequence homology to a wild-type human AKR1 protein selected from the group consisting of AKR1B1, AKR1B10, AKR1B15, and AKR1C3.

10. The composition of claim 9, wherein the modified AKR1 protein has between 80% and 99% homology to the wild-type human AKR1 protein.54578332772Attorney Docket No. 047162-7558 WO 1 (02937)11. The composition of any one of claims 1-10, further comprising a pharmaceutically acceptable carrier.

12. A method of treating a subject having lung inflammation, the method comprising administering to a subject in need thereof a composition of any one of claims 1-11.

13. The method of claim 12, wherein the administering comprises intranasal administration, intratracheal administration, intravenous (IV) administration, inhalation administration, or a combination thereof.

14. The method of any one of claims 12-13, wherein the lung inflammation is acute lung inflammation.

15. The method of claim 14, wherein the administering of the composition reduces pulmonary damage caused by the acute lung inflammation.

16. The method of claim 12, wherein the lung inflammation is caused by a lung inflammation-related disease.

17. The method of claim 16, wherein the lung inflammation related disease comprises acute respiratory distress syndrome (ARDS), a bacterial infection, bacterial infection-related pneumonia, a viral infection, an ischemia-reperfusion injury, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, cystic fibrosis, asthma, or a combination thereof.

18. The method of claim 17, wherein the lung inflammation-related disease is acute respiratory distress syndrome (ARDS).

19. The method of claim 18, wherein the administering of the composition reduces ferroptosis in the subject.

20. The method of claim 19, wherein the administering of the composition reduces ferroptotic alveolar cell death in the subject.55578332772Attorney Docket No. 047162-7558 WO 1 (02937)21. The method of claim 17, wherein the viral infection is respiratory syncytial virus (RSV) infection, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle Eastern respiratory syndrome coronavirus (MERS-CoV), other coronavirus infection, or a combination thereof.

22. The method of any one of claims 12-21, wherein the administering of the composition reduces at least one of pulmonary permeability, lipid peroxidation, and ferroptotic alveolar cell death in the subject.56578332772